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Abstract 
This dissertation aimed at filling the gaps in the body of multiple myeloma (MM) literature by 
comparing overall survival and safety of first line maintenance or continuous treatment, and 
assessing disease lifetime costs, phase-specific costs and its drivers among elderly newly 
diagnosed (NDMM) patients. Moreover, it aimed to assess trends in EOL care and the impact of 
PCC on EOL care outcomes among elderly MM patients. 
First, this study assessed the comparative safety and effectiveness among those who 
received first line LEN-based treatment versus those who received first line BORT-based 
treatment. The results from the study demonstrates an overall survival benefit and similar 
toxicity risk for patients receiving first line LEN-based continuous or maintenance treatment 
over those who received first line BORT-based treatment.  
Further, the study results highlighted the substantial economic burden associated with 
MM care, in spite of the disease having low prevalence as compared to some of the other 
cancers. The incremental phase-specific costs were highest for the initial care phase, followed by 
the terminal phase, with costs being slightly lower for the continuing care phase, and lowest for 
the pre-diagnosis phase. Inpatient and outpatient costs were the major drivers of costs in all the 
four phases. Pharmacy costs were a significant driver of costs in the initial and terminal phases, 
and were the biggest cost driver in the continuing care phase. 
Last, it assessed trends in aggressiveness of EOL care outcomes over time. While certain 
indicators of aggressive EOL care remained stable over time, we observed an increasing trend 
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for multiple ED visits and ICU stays. Moreover, this study assessed the impact of palliative care 
consultations on receiving aggressive EOL care, and healthcare resource use and costs at EOL. 
Results indicate that early palliative care consultations have the potential to reduce aggressive 
EOL care, and curtail healthcare resource use and costs at EOL. 
Study findings about clinical and economic outcomes will help inform clinicians’ 
treatment decisions, aid policy discussions regarding MM care and coverage, and help design 
interventions to integrate early palliative care into routine care among elderly MM patients. 
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CHAPTER 1 
INTRODUCTION 
Multiple myeloma 
Overview of multiple myeloma 
 Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal clonal 
growth of the plasma cells. It results from an asymptomatic premalignant growth of monoclonal 
plasma cells originating from post-germinal-center B cells (Palumbo and Anderson 2011).  MM 
most commonly evolves from monoclonal gammopathy of undetermined clinical significance 
(MGUS). In over half of all MM patients, primary translocations involving immunoglobulin 
heavy chain (IgH) locus on chromosome 14q32 drives the clonal plasma cell proliferation in 
MGUS (Kuehl and Bergsagel 2002; Bergsagel and Kuehl 2001; Rafael Fonseca et al. 2002; 
Seidl, Kaufmann, and Drach 2003). Even though the exact mechanism for evolution of MGUS 
into MM is unknown, genetic abnormalities and bone marrow microenvironment changes like 
angiogenesis, cell-mediated immunity suppression, and alterations in various cytokines play an 
important role in the process (Kuehl and Bergsagel 2002; Bergsagel and Kuehl 2001; Rafael 
Fonseca et al. 2002; Hideshima and Anderson 2002; Rajkumar et al. 2002). The course of MM 
usually starts with a diagnosis phase, followed by a prolonged treatment phase aimed at 
extending overall survival (OS) and progression-free survival (PFS). MM treatment usually 
consists of an induction phase, followed by stem cell transplant (SCT) and a long maintenance 
phase post SCT for SCT eligible MM patients (McCarthy et al. 2017; Attal et al. 2017), or  
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continuous maintenance phase, typically a low dose extension of induction phase for SCT-
ineligible MM patients (Musto and Montefusco 2016).  
Diagnosis 
 MM is defined as either asymptomatic (SMM or smoldering multiple myeloma) or 
symptomatic based on the absence or presence of hypercalcemia, renal insufficiency, anemia, 
and bone disease, which is also known as the CRAB criteria (B. G. Durie et al. 2003; B. G. M. 
Durie et al. 2006; Kyle and Rajkumar 2009). As per the International Myeloma Working Group 
(IMWG), MGUS is defined as presence of less than 3g/dL of serum M-protein and < 10% 
monoclonal plasma cells in the bone marrow. MM is defined as SMM if serum M-protein levels 
are ≥3 mg/dL, or if there are ≥10% monoclonal plasma cells in the bone marrow. Symptomatic 
MM is defined as presence of end organ damage (CRAB criteria) in addition to  ≥3 mg/dL serum 
M-protein levels or presence of  ≥10% monoclonal plasma cells in the bone marrow 
(International Myeloma Working Group 2003; Kyle et al. 2010). In 2014, the IMWG defined 
“ultra-high risk” SMM as SMM with ≥ 80% risk of progressing to symptomatic MM within two 
years, based on presence of ≥ 60% bone marrow plasma cell burden, an involved to uninvolved 
light chain ratio of ≥ 100, and 2 or more lytic lesions detected from spine MRI (Rajkumar et al. 
2014). According to the International Staging System (ISS), symptomatic MM is categorized 
into three risk groups (stages I, II, and III) based on the levels of serum β2-microglobulin and 
albumin levels (Greipp et al. 2005).    
 In addition to detailed physical examination and review of medical history, MM 
diagnosis is made through tests for complete blood count, chemical analysis, serum and urine 
protein electrophoresis with immunofixation, quantification of monoclonal protein, and bone 
marrow examination (R. Fonseca et al. 2009; Kyle and Rajkumar 2009). Myeloma-related bone 
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lesions are usually identified through conventional radiography and MRI of the spine, skull, 
chest, pelvis, humeri, and femora (Kyle and Rajkumar 2009; Dimopoulos et al. 2009). 
Epidemiology 
MM is the most common blood cancer after lymphoma and leukemia, accounting for 
approximately 1.6% of all new cancer cases in the United States (US) in 2015 (Chen et al. 2017). 
According to data from the American Cancer Society (ACS), MM has a lifetime risk of 1 in 132 
(0.8%) in the US. An estimated 30,770 new cases of MM (16,400 men and 14,370 women) were 
diagnosed and 12,770 patients (6,830 men and 5,940 women) died from MM in the US in 2018 
(American Cancer Society 2018). According to data from the National Cancer Institute’s (NCI) 
Surveillance, Epidemiology, and End Results (SEER) program, the estimated 5-year survival rate 
for MM is 51%, and depends on individual patient characteristics such as age and stage at 
diagnosis among others (National Cancer Institute, Surveillance, Epidemiology and End Results 
Program. 2019). MM has a higher prevalence in men, among individuals of African American 
origin, and amongst the elderly. The median age at diagnosis of MM is 69 years, with majority of 
the individuals diagnosed at an age of 65 or greater (Noone AM, Howlader N, Krapcho M, 
Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, 
Cronin KA (eds) 2018).   
Treatments 
MM treatment has seen a paradigm shift in the past few decades, first with the 
development of autologous stem cell transplant (ASCT), and then with the approval of novel 
agents, such as immunomodulatory drugs (IMIDs) - thalidomide and lenalidomide, and 
proteasome inhibitor (PI) bortezomib in the 2000s. The introduction of ASCT and novel agents 
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have led to drastic changes in MM management, and prolonged overall survival (Brenner, 
Gondos, and Pulte 2008; Kristinsson et al. 2007; S. K. Kumar et al. 2008). The last few years 
have seen even more modifications in the treatment landscape for MM with approvals of IMID 
pomalidomide in 2013, PIs carfilzomib and ixazomib in 2012 and 2015 respectively, and 
monoclonal antibodies daratumumab and elotuzumab in 2015 (R. Fonseca et al. 2017). MM 
treatment varies by patient’s age and other clinical characteristics such as frailty, comorbidities, 
and disability status (Weisel et al. 2017). The recommended treatment for patients younger than 
70 years and of good health status includes induction therapy with novel agents, followed by 
ASCT and maintenance therapy (McCarthy et al. 2017; Attal et al. 2017b). The standard 
treatment for ASCT-ineligible patients is continuous maintenance therapy with IMID or PI, 
which is typically a prolonged course of the induction therapy (Musto and Montefusco 2016).  
Maintenance therapy aims to prolong the length of disease remission through continuous 
treatment, with several studies reporting maintenance and continuous therapy to have led to 
significant improvements in both PFS and OS (Sonneveld et al. 2012; Bahlis et al. 2017; S. 
Kumar et al. 2017; Richardson et al. 2017). Lenalidomide (LEN) or bortezomib (BORT) 
maintenance therapy are recommended as first-line for both ASCT-eligible and ASCT-ineligible 
MM patients, according to the National Comprehensive Cancer Network Clinical Practice 
Guidelines (S. K. Kumar et al. 2017). Furthermore, while there are clinical benefits of 
maintenance or continuous treatment with LEN- and BORT-based regimens, toxicities 
associated with the use of these agents, such as neuropathy, cardiac toxicity, thrombocytopenia, 
neutropenia, and tumor lysis syndrome, can limit their sustained use (Bringhen et al. 2017; 
Wang, Li, and Yan 2016; Ludwig et al. 2017; Burnette et al. 2013).  
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Economic burden 
Cost associated with cancer treatment poses a significant burden to patients and their 
family members, payers, and society in general. The estimated total direct medical costs 
attributable to cancer treatment in the US was around $125 billion in 2010 (Roy et al. 2015). 
Even though MM accounts for a small proportion of patients with cancer, healthcare costs 
associated with treatment of MM are higher than treatment of most other types of cancer (Cook 
2008). Studies that have incremental costs associated with MM have reported a significant 
increase in costs in the past decade, with outpatient costs, hospitalizations, and drug costs 
identified as drivers of increase in costs (R. Fonseca et al. 2017; Petrucci et al. 2013).  
Most of the studies that have assessed disease-related costs in MM have used a 
prevalence-based approach. It is important to assess healthcare expenditures across phases of 
MM care. This is due to the fact that as disease progresses, treatments differ and thus, costs differ 
by each phase of MM care (de Oliveira et al. 2016). Extant literature on healthcare costs among 
cancer patients suggest that healthcare expenditures across the disease continuum follows a U-
shaped curve, with greater expenditure happened around the time of diagnosis (initial care phase) 
and death (terminal phase), and lower expenditures incurred in the continuing care phase 
between the initial care phase and the terminal phase. These studies have also shown that such 
phase-based cost estimates in combination with survival estimates yield reliable estimates of 
long-term disease burden (Brown et al. 1999, 2002; de Oliveira et al. 2013; Krahn et al. 2010; 
Yabroff et al. 2008). However, there is very limited literature on disease lifetime costs of MM. 
One study, conducted using data from the Ontario Cancer Registry reported that the costs of MM 
patients were higher in the initial care phase and terminal phase, and lower in the continuing care 
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phase and pre-diagnosis period. This study also found that MM has the highest disease lifetime 
costs  among of all types of cancer (de Oliveira et al. 2016).    
End of life care 
 End of life (EOL) care is defined as “comprehensive care for life-limiting illnesses that 
meets the patient’s medical, physical, psychological, spiritual, and social needs” (National 
Quality Forum 2012). It is very important to appropriately manage EOL care in order to ensure 
that patients receive medical care that is of high quality and cost-effective at the same time. A 
Medicare analysis revealed that even though around 5% of the beneficiaries die each year, they 
account for around 30% of total Medicare expenditures, and around 33% of costs incurred in the 
last year of life are attributable to the last month before death (Emanuel et al. 2002). Aggressive 
medical care before death is neither beneficial from a clinical perspective nor from a humanistic 
point of view. A study conducted across several cancer care centers across the US revealed that 
higher treatment costs in the last week of death was associated with poorer quality of life among 
patients with advanced cancer (Zhang et al. 2009). It has been reported that patients with 
hematological malignancies, including MM, receive more aggressive cancer-related care near 
death and have lower use of palliative care and hospice services as compared to patients with 
solid tumors (Earle et al. 2008; Ho et al. 2011; Hui et al. 2012; Sexauer et al. 2014; Tang et al. 
2009; Cheng et al. 2005). The difference in quality of EOL care between hematologic cancers 
and solid cancers can be attributed to a variety of reasons. One of the major barriers towards 
inception of EOL care among patients with hematologic cancers is lack of clarity on onset of 
EOL. This problem is compounded by the availability of treatments in advanced stages and the 
rapid  decline of patient’s health near death (Fadul et al. 2008). Other factors that have been 
reported as barriers to quality of EOL care among patients with hematologic cancers include 
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unrealistic patient expectations and difficulties in conducting EOL discussions with patients 
(Odejide et al. 2014). Another key consideration in EOL care is variations in regional practice 
patterns. Previous studies have reported regional clinic practice norms, including physician’s 
beliefs, and availability of medical resources to be predictors of EOL care decisions (Barnato et 
al. 2012; Keating et al. 2018). Studies have also reported regional practice patterns to be drivers 
of geographical variation in healthcare utilization and costs (B. E. Sirovich et al. 2005; B. 
Sirovich et al. 2008).  
The treatment landscape in MM has seen a drastic change in the past two decades with 
the advent of stem cell transplant and novel agents. While patients with MM are living longer, 
the burden of the disease and side effects of the treatments often lead to high symptom burden. 
Studies have reported high prevalence of pain, fatigue and drowsiness among MM patients 
(Snowden et al. 2011; Porta-Sales et al. 2015; Niscola et al. 2007). This underlines the need for 
holistic assessment of MM patients and compliment cancer-directed treatment with palliative 
care, as evidenced by supportive care guidelines in MM (Snowden et al. 2011).   
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Need for the Study 
Even though there is significant evidence for the clinical benefit of maintenance therapy 
and both LEN- and BORT- based regimens can be used as first line treatment, there is no clear 
consensus on the superiority of one treatment over the other due to the lack of direct 
comparisons. Moreover, most of the data regarding the clinical benefits of various treatment 
regimens are from clinical trials, with very limited real world evidence available. It is important 
to assess the effectiveness of maintenance therapies in real-world settings since MM is typically 
a disease of the elderly, who are underrepresented in RCTs, as comorbidities, frailty, and 
disability often lead to elderly patients being excluded from clinical trials (Hutchins et al. 1999). 
Additionally, there is very limited real world evidence on the comparative safety of LEN-based 
and BORT-based therapies, especially in a population of elderly newly diagnosed MM (NDMM) 
patients. An assessment of comparative safety and effectiveness of LEN-and BORT-based 
maintenance and continuous treatments would help clinicians in selecting the most appropriate 
therapy for elderly NDMM patients.  
 While real-world studies have assessed healthcare expenditures among MM patients, 
most of these studies have been limited to assessment of healthcare costs in various lines of 
treatment (e.g., first-line vs second-line) or examination of treatment-related costs (novel agent 
use versus other therapy) (MacEwan et al. 2018; Arikian et al. 2015; Teitelbaum et al. 2013). 
Given that majority of the MM patients in the US are diagnosed at an age of 65 or greater, and 
that Medicare is the primary payer for this population, and taking into consideration the changing 
landscape of MM treatment with introduction of several novel agents, it is important to assess the 
disease lifetime costs of MM from Medicare’s perspective. However, no study in the US has yet 
evaluated the disease lifetime costs of MM from Medicare’s perspective. A better understanding 
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of healthcare costs attributable to MM over the disease lifetime and across various phases of 
cancer care, and the drivers of these costs would help plan interventions and policy decisions 
targeted towards improving quality of cancer care while controlling costs (Kaye et al. 2018).  
 While a few studies have assessed trends in EOL care in hematologic malignancies in 
general, no study has yet assessed trends in EOL care among MM patients. Similarly, there is 
very limited evidence on the impact of palliative care services on quality of care, healthcare 
utilization, and costs at EOL. Given the changing landscape of MM treatment and the significant 
symptom burden associated with the disease, assessing trends in quality of EOL care among MM 
patients will help policy makers and medical decision makers aim tailored intervention programs 
to improve quality of EOL care. Moreover, evidence regarding the impact of palliative care 
consultation on quality of EOL care, healthcare utilization and costs could be used by clinicians 
and policy makers to better integrate palliative care with routine cancer care among MM 
patients.  
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Specific Aims and Objectives 
The aim of this study is to assess the comparative effectiveness and safety of LEN-based versus 
BORT-based maintenance and continuous treatments, estimate phase-specific costs attributable 
to MM and its drivers as well as the disease lifetime costs of MM, and to assess trends in quality 
of EOL care in MM and effect of palliative care consultations on quality of EOL care, healthcare 
utilization at EOL, and costs at EOL among elderly NDMM patients enrolled in Medicare using 
SEER-linked Medicare administrative claims data. The specific study aims and objectives are as 
follows:  
1. To assess the comparative effectiveness and safety of first-line maintenance and 
continuous treatment with LEN-based vs BORT-based therapies among elderly patients 
with NDMM  
a. To assess treatment patterns and duration of first-line LEN-based vs BORT-based 
maintenance and continuous treatment among elderly NDMM patients enrolled in 
Medicare  
b. To compare the effectiveness of first-line LEN-based vs BORT-based 
maintenance and continuous treatment among elderly NDMM patients enrolled in 
Medicare  
c. To compare safety of first-line LEN-based vs BORT-based maintenance and 
continuous treatment among elderly NDMM patients enrolled in Medicare  
2. To assess disease lifetime costs and its predictors among elderly patients with NDMM 
a. To identify duration of initial care phase and terminal care phase among elderly 
patients with NDMM using Joinpoint regression  
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b. To assess phase-specific costs and drivers of phase-specific costs among elderly 
patients with NDMM  
c. To assess disease lifetime costs among elderly patients with NDMM    
3. To assess trends in EOL care and the impact of palliative care consultations on EOL care 
outcomes among elderly patients with NDMM 
a. To assess trends in quality of EOL care among elderly patients with NDMM  
b. To assess the impact of palliative care consultations on quality of EOL care, 
accounting for variations in regional practice patterns, among elderly newly 
diagnosed MM patients   
c. To assess the impact of palliative care consultations on healthcare resource 
utilization and costs at EOL, accounting for variations in regional practice 
patterns, among elderly newly diagnosed MM patients                   
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CHAPTER 2: PAPER 1 
Comparative Effectiveness and Safety of Lenalidomide-based and Bortezomib-based 
Maintenance and Continuous Treatment among Elderly Patients with Newly Diagnosed 
Multiple Myeloma  
Introduction 
Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal clonal growth 
of the plasma cells. It is associated with significant mortality and morbidity, especially due to 
end organ damage such as renal impairment, hypercalcemia, bone lesions, and anemia.(Cowan et 
al. 2018) MM is the most common blood cancer after lymphoma and leukemia, accounting for 
approximately 1.6% of all new cancer cases in the United States (US) in 2015.(Y. Chen et al. 
2017) According to data from the American Cancer Society (ACS), MM has a lifetime risk of 1 
in 132 (0.8%) in the US. An estimated 30,770 new cases of MM (16,400 men and 14,370 
women) were diagnosed and 12,770 patients (6,830 men and 5,940 women) died from MM in 
the US in 2018.(American Cancer Society 2018) According to data from the National Cancer 
Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) program, the estimated 5-
year survival rate for MM is 51%, and depends on individual patient characteristics such as age 
and stage at diagnosis among others.(National Cancer Institute, Surveillance, Epidemiology and 
End Results Program. 2019) MM has a higher prevalence in men, among individuals of African 
American origin, and amongst the elderly. The median age at diagnosis of MM is 69 years, with 
majority of the individuals diagnosed at an age of 65 or greater.(Noone AM, Howlader N,
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 Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, 
Feuer EJ, Cronin KA (eds) 2018)  
MM treatment has changed drastically over the past few decades. The first major breakthrough 
in MM treatment came with the development of autologous stem cell transplant (ASCT), 
followed by introduction of novel agents such as immunomodulatory imide drugs (IMIDs) and 
proteasome inhibitors.(Cowan et al. 2018) The introduction of these novel agents, along with 
ASCT and high-dose chemotherapy, has led to substantial improvements in clinical outcomes of 
MM patients.(Lehners et al. 2018) The median survival of a newly diagnosed MM (NDMM) 
patient has increased from 2.5 years to 5-7 years.(Donk and Lokhorst 2013) MM treatment varies 
by patient’s age and other clinical characteristics such as frailty, comorbidities, and disability 
status.(Weisel et al. 2017) The recommended treatment for patients younger than 70 years and of 
good health status includes induction therapy with novel agents, followed by ASCT and 
maintenance therapy with IMID or proteasome inhibitor (PI) (Attal et al. 2017; McCarthy et al. 
2017). The standard treatment for ASCT-ineligible patients is continuous maintenance therapy 
with IMID or PI, which is typically a prolonged course of the induction therapy (Musto and 
Montefusco 2016).  
 Maintenance therapy aims to prolong the length of disease remission through continuous 
treatment, improving progression-free survival (PFS) and overall survival (OS).(Anderson et al. 
2008) Several studies have shown maintenance and continuous therapy to lead to significant 
improvements in both PFS and OS.(Sonneveld et al. 2012; Richardson et al. 2017; S. Kumar et 
al. 2017; Bahlis et al. 2017) Lenalidomide (LEN) or bortezomib (BORT) maintenance therapy 
are recommended as first-line for both ASCT-eligible and ASCT-ineligible MM patients, 
according to the National Comprehensive Cancer Network Clinical Practice Guidelines.(S. K. 
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Kumar et al. 2017) Several studies have shown LEN or BORT maintenance to have a beneficial 
impact on MM patients’ clinical outcomes, in both transplant-eligible and transplant-ineligible 
settings. Among patients that undergo transplant, randomized clinical trials assessing impact of 
LEN maintenance treatment post-ASCT have found benefits in PFS among most of the patients, 
except for those with stage III cancer at diagnosis and high-risk cytogenetics.(McCarthy et al. 
2012; Attal et al. 2012; Palumbo et al. 2014) Similarly, evidence for improved PFS and OS with 
BORT-based induction and maintenance therapy has been obtained from the phase 3 HOVON-
65/GMMG-HD4 trial.(Sonneveld et al. 2012; Neben et al. 2012) Previous studies evaluating the 
effect of maintenance therapy have also reported improved clinical outcomes with both LEN-
based(Stewart et al. 2015; Dimopoulos et al. 2015; Bringhen et al. 2017; Benboubker et al. 2014; 
Facon et al. 2018) and BORT-based(Palumbo et al. 2010; Mateos et al. 2010; 2012; Niesvizky et 
al. 2015) maintenance regimens among MM patients who are ineligible for transplant.        
 Even though there is significant evidence for the clinical benefit of maintenance therapy 
and both LEN- and BORT- based regimens can be used as first line treatment, there is no clear 
consensus on the superiority of one treatment over the other due to the lack of direct 
comparisons. Moreover, most of the data regarding the clinical benefits of various treatment 
regimens are from clinical trials, with very limited real world evidence available. It is important 
to assess the effectiveness of maintenance therapies in real-world settings since MM is typically 
a disease of the elderly, who are underrepresented in RCTs, due to the fact that comorbidities, 
frailty, and disability often lead to elderly patients being excluded from clinical trials.(Hutchins 
et al. 1999) A real-world single center study in the US compared LEN maintenance and BORT 
maintenance vs no maintenance among MM patients who had undergone early ASCT. It found 
LEN-based maintenance has superior PFS (37 months vs 28 months) as compared to no 
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maintenance irrespective of patient’s cancer stage and cytogenesis at diagnosis. While BORT-
based maintenance did not show significantly better PFS for the entire cohort, it had superior 
PFS (28 months vs 16 months) for the high-risk cytogenetic patient subgroup (Chakraborty et al. 
2018). Only one real-world study has assessed the comparative effectiveness of LEN vs BORT 
maintenance therapy among MM patients post stem cell transplant in the US. It did not find any 
significant differences in OS or PFS between LEN and BORT maintenance treatments. However, 
the study was limited by its small sample size and generalizability.(Huang et al. 2018)    
 While maintenance or continuous treatment with LEN- and BORT-based regimens have 
been associated with clinical benefits among MM patients, toxicities associated with the use of 
these agents can limit their sustained use.(Bringhen et al. 2017) A meta-analysis of RCTs on 
novel agent based treatments in MM patients reported LEN-based treatment were statistically 
significantly associated with neutropenia, anemia, thrombocytopenia, gastrointestinal (GI) 
events, and thrombosis, while BORT-based regimens were significantly associated with 
peripheral neuropathy (PN), and thrombocytopenia.(Wang, Li, and Yan 2016) Toxicities 
common to both LEN- and BORT-based treatments include neuropathy, cardiac toxicity, 
thrombocytopenia, neutropenia, and tumor lysis syndrome.(Ludwig et al. 2017) The toxicity 
burden of maintenance therapies also influences patient preference for these treatments. A survey 
of 1,159 MM patients in the US found toxicity to be associated with reduction in proportion of 
patients willing to opt for maintenance therapy.(Burnette et al. 2013) A real-world study of LEN-
based and BORT-based maintenance treatments reported 17% and 7% discontinuation rate due 
to toxicity for LEN-based and BORT-based maintenance respectively. (Chakraborty et al. 2018) 
 Even though it is important to assess the comparative safety of LEN- and BORT-based 
therapies, very few real world studies have done that. A US single center comparison of LEN-
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based vs BORT based maintenance regimens among NDMM patients post-transplant reported 9 
patients (9.8% of all patients receiving LEN maintenance) in the LEN group discontinued 
treatment due to a serious adverse event as compared to 8 patients (12.5% of all patients 
receiving BORT maintenance) in the BORT group.(Huang et al. 2018) A retrospective analysis 
of administrative claims data among MM patients with private insurance and Medicare 
Advantage plans found similar cardiotoxicity risk among those who used BORT-based regimens 
versus those who used LEN-based regimens.(Reneau et al. 2017) However, this study only 
included cardiac toxicity associated with BORT or LEN use but not the other toxicities. In the 
current study, we aim to assess the treatment patterns and to compare the clinical effectiveness 
and safety of LEN- and BORT-based treatments among elderly NDMM patients using real-world 
data. This information, of direct comparison of LEN-based and BORT-based maintenance or 
continuous treatments, could be used by clinicians to select the most appropriate therapy for 
NDMM patients.  
Methods 
Data Source and Study Design  
A retrospective analysis was conducted using National Cancer Institute’s (NCI) SEER database 
linked with Medicare administrative claims database. The NCI’s SEER program is an 
epidemiologic surveillance system that contains data collected from population-based tumor 
registries and was designed to track cancer incidence and mortality in the US. It includes clinical 
and demographic information in addition to information on cause of death for people with 
cancer, and is collected from 18 participating cancer registries across the US. Medicare is a 
federally administered health insurance program which covers elderly Americans who are 65 
years of age or older, as well as younger patients with disabilities and end-stage renal disease 
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(ESRD). The Medicare administrative claims database provides information on claims for 
covered healthcare services for beneficiaries enrolled in Medicare. The SEER-linked Medicare 
claims database provides patient-level data for Medicare beneficiaries with cancer.(Warren et al. 
2002)  
The current study utilized 2007-2015 SEER data linked with 2006-2016 Medicare claims 
data. The SEER data consists of the Patient Entitlement and Diagnosis Summary File (PEDSF) 
that includes clinical, demographic, and Medicare enrollment information for individuals with 
cancer. The Medicare claims data consists of the Medicare Provider Analysis and Review 
(MEDPAR), National Claims History (NCH), Outpatient (OUTPT), Home Health Agency 
(HHA), Hospice, Durable Medical Equipment (DME), and Prescription Drug Event (PDE) files. 
The MEDPAR file contains all Medicare Part A claims indication short stay, long stay, skilled 
nursing facility (SNF) stays as well as ICD-9/10 diagnoses and procedures performed during 
each stay. The NCH file contains all Medicare Part B claims generated due to physician or 
supplier services in clinics and hospitals, whereas the OUTPT file contains all Medicare Part B 
claims outpatient providers. Both NCH and OUTPT files were used to obtain information such 
as procedural Healthcare Common Procedure Coding System (HCPCS) codes, diagnoses, date of 
claims, treatment administration, and reimbursement amounts. The HHA file contains claims for 
all home health care services such as number and types of visits and diagnoses. The hospice file 
contains claims submitted by hospice providers, and has details on type of care (inpatient care, 
routine home care) as well as terminal diagnosis associated with that care. The DME file 
contains claims with information on use of oral and intravenous chemotherapy, and infusion 
pumps used. The PDE file contains information about drug utilization such as, date of 
prescription fill, drug dispensed, quantity dispensed, days supplied, total cost, and out-of-pocket 
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cost. The Institutional Review Board (IRB) at the University of Mississippi has approved the 
study.  
Study sample 
This study included Medicare beneficiaries who entered the SEER registry from 2007 through 
2015, and were diagnosed with MM as their primary cancer. All beneficiaries with primary MM 
were identified based on the International Classification of Diseases for Oncology, 3rd Edition 
(ICD-O-3) code of MM (9732). Additionally, patients needed to be 66 years of age or older at 
the time of MM diagnosis and be continuously enrolled in Medicare Parts A and B in the 12 
months prior to the month of MM diagnosis to be included in the study. The 12-month pre-
diagnosis baseline period was used to obtain clinical information on comorbidities. Furthermore, 
patients needed to have continuous enrollment in Medicare Parts A, B, and D for at least 2 
months post-MM diagnosis to be included. Patients were excluded from the study sample if they 
had an unknown diagnosis month or year, or if MM diagnosis was made at the time of death. 
Moreover, MM patients were excluded from the study sample if they had any cancer in the 5 
years prior to MM diagnosis, or if they were enrolled in a health maintenance organization 
(HMO) in the 12-month pre- and post- MM diagnosis period.   
Study Variables       
Treatment patterns for continuous or maintenance treatment were assessed for all elderly NDMM 
patients included in the study sample. For each line of therapy, Duration of treatment was 
defined as the number of days between the index date (start date for the specific line of therapy) 
and treatment discontinuation (switch to a different line of therapy or no treatment) or end of 
study period. Time spent in each line of therapy was calculated using the time-to-next-treatment 
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approach (TTNT). TTNT was defined as the number of days spent on a particular therapy 
regimen until a new treatment was added to the current line of therapy or switch to a new drug 
regimen, or a gap in therapy of 90 or more days in current therapy. This is consistent with 
previous studies that have assessed treatment patterns among MM patients (C.-C. Chen et al. 
2017).      
Patients were assigned to LEN-based or BORT-based maintenance or continuous 
treatment cohorts based on index claims for first-line LEN or BORT treatment in the follow-up 
period post stem cell transplant (SCT) for those who underwent SCT, or follow-up period post 
MM diagnosis for those who did not undergo SCT respectively. Claims for LEN and BORT 
were identified using HCPCS codes and National Drug Codes (NDCs) respectively. The first 
claim date for LEN or BORT treatment were referred to as index treatment date.  
For patients in both the cohorts (LEN maintenance and BORT maintenance), outcome 
variables assessed included duration of therapy, survival, and safety. Duration of therapy was 
defined as the number of days from index treatment date until a gap in treatment of greater than 
90 days, a measure that  has been previously used in SEER-Medicare analyses evaluating 
duration of cancer therapy.(Griffiths et al. 2011) Furthermore, treatment switch was defined as 
treatment discontinuation or initiation of a new treatment after a gap of greater than 90 days for 
previous treatment. Survival was operationalized as time from index treatment date to all-cause 
death. The date of death was obtained from the Medicare date. SEER date of death was used in 
case Medicare death date is missing.(Griffiths et al. 2011) The safety events included peripheral 
neuropathy, thrombocytopenia, neutropenia, tumor lysis syndrome, cardiac toxicity. A composite 
outcome measure of any of these safety events was also assessed. Cardiac toxicity for MM 
treatments included heart failure (HF), myocardial infarction (MI), and arrhythmia. Medical 
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claims for the 12-month pre index treatment period will be evaluated to control for prior history 
these events. Safety outcomes were binary events indicating whether a patient had a safety event. 
Time to safety events were assessed by calculating number of days between index treatment date 
and date of first safety event.  
Baseline demographic covariates included age (at MM diagnosis), gender, race/ethnicity, 
region, rural/urban status, and marital status. Baseline clinical covariates included comorbidity, 
disability status, and receipt of SCT (using 5 digit HCPCS code for SCT). Comorbidity was 
assessed using the Deyo adaption of the Charlson Comorbidity Index (CCI).(Deyo, Cherkin, and 
Ciol 1992) Disability status, which is a proxy measure for performance status, was calculated 
using a validated, claim-based algorithm during the 12-month baseline period prior to MM 
diagnosis.(Davidoff et al. 2013)  
Data Analysis 
Propensity score matching was employed to account for covariate imbalance at baseline between 
the LEN and BORT treatment cohorts. A 1:1 match without replacement was performed based 
on the patients’ propensity to be treated with LEN. Logistic regression was employed to obtain 
the propensity scores, and will be modeled based on age, gender, race, region, rural/urban status, 
marital status, receipt of SCT, disability status, and CCI score. Mean standardized differences 
were used to assess covariate imbalance between the two groups post propensity score matching. 
A standardized difference less than 0.1 was considered to be negligible (Austin 2011).  
Summary of baseline clinical and demographic characteristics of the study sample was 
presented. For categorical variables, frequency and percentage distributions were reported. 
Descriptive statistics were used to depict baseline patient characteristics, treatment patterns, 
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survival, safety, and duration of therapy. For categorical variables, frequency and percentage 
distributions were reported. Statistical comparisons between the two groups were conducted 
using McNemar’s test or Cochrane-Mantel-Haenszel test, to account for the matched data. For 
continuous variables, mean, standard deviation (SD), median, and range were reported. 
Statistical comparisons for continuous variables were conducted using paired t-tests. Descriptive 
summary for survival, duration of therapy, and time to safety events were conducted using 
unadjusted Kaplan-Meier survival analysis.  
Cox Proportional Hazards models were used to compare the LEN and BORT treatment 
cohorts on survival, duration of therapy and safety, adjusting for demographic and clinical 
covariates. For each of the models, a robust variance estimator was used to account for clustering 
within matched pairs. For survival, patients were censored at death, treatment switch, or loss of 
Medicare eligibility or end of study period, whichever occurred first. For duration of therapy, 
patients were censored at treatment switch, loss of Medicare eligibility, end of study period, or 
death, whichever occurred first. For safety, patients were censored at first safety event, treatment 
switch, loss of Medicare eligibility, or end of study period whichever occurred first. Moreover, 
for each of the safety outcomes, any prior history of the safety events were controlled for in the 
analysis. For each of the Cox Proportional Hazards models, the proportional hazards assumption 
was assessed using Schoenfeld residuals and interactions with time for each of the model 
predictors. Significant results (p<0.05) indicated a violation of the proportional hazards 
assumption. In such cases, Stratified Cox Proportional Hazards models with robust variance 
estimators were employed, stratified on the variable that violated the proportional hazards 
assumption.    
All data management and analysis will be done using SAS version 9.4.(SAS. (2015), n.d.)   
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Results 
6,343 elderly NDMM patients met the study inclusion and exclusion criteria. The demographic 
and clinical characteristics of the study sample are presented in Table 1.1. Most of the elderly 
MM patients in the sample lived in urban areas (88.4%), were white (74.2%), did not have 
disability at baseline (76.8%), and did not undergo SCT (92.1%). Additionally, majority of the 
elderly NDMM patients in the sample were female (53.1%), 75 years old or older at baseline 
(54.9%), had a CCI score of 2 or more at baseline (56.3%), and resided in the western or 
southern (67.1%) region of the US. Moreover, majority of the MM patients in the sample were 
either married (48.9%) or widowed (25.5%) at the time of MM diagnosis. Furthermore, 17.3% of 
the elderly NDMM patients did not receive any continuous or maintenance therapy, 35.3% 
received one line of continuous or maintenance therapy, 20.9% received two lines of continuous 
or maintenance therapy, 12.4% received three lines of continuous or maintenance therapy, and 
14.1% received four or more lines of continuous or maintenance therapy.  
 Table 1.2 depicts the patterns of continuous or maintenance treatment among elderly 
NDMM patients. Of all the elderly NDMM patients in the study sample, 82.7% had at least one 
line, 47.4% had two or more lines, and 26.5% had three or more lines of continuous or 
maintenance treatment. For those who received first line of continuous or maintenance treatment, 
33.1% received BORT-based treatment, 22.4% received LEN-based treatment, and 6.2% 
received thalidomide (THAL)-based treatment. Moreover, 13.7% and 24.6% of the elderly 
NDMM patients who received first line treatment received combination anti-MM drug regimens 
and other drug regimens (chemotherapy and/or corticosteroids only) respectively. For those who 
received second line treatment, 25.1% received BORT-based treatment, 20.9% received LEN-
based treatment, and 3.8% received THAL-based treatment. Additionally, 24.2% and 26.0% of 
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the elderly NDMM patients who received second line treatment received combination anti-MM 
drug regimens and other drug regimens respectively. For third line treatment, 24.6% received 
BORT-based treatment, 17.9% received LEN-based treatment, and 2.1% received THAL-based 
treatment. Furthermore, 24.1% and 31.3% of the elderly NDMM patients who received third line 
treatment received combination anti-MM drug regimens and other drug regimens respectively. 
Moreover, the median duration of first line treatment was 195 days [interquartile range (IQR): 
118-360 days], median duration of second line treatment was 194 days [IQR: 113-352 days], and 
median duration of third line treatment was 168 days [IQR: 109-303 days].  
 To assess the comparative effectiveness and safety of first line LEN-based vs BORT-
based continuous or maintenance treatment, 1,022 elderly NDMM patients with first line LEN-
based regimen were matched on age, urban residency, geographical region, gender, race, marital 
status, disability status, receipt of SCT, and CCI score to 1,022 elderly NDMM patients with first 
line BORT-based regimen. As seen in Table 1.3, the standardized mean difference was 
negligible between the two groups for all covariates included in the propensity score (P-S) 
matched model.  
 Results from unadjusted Kaplan-Meier (K-M) survival analysis show that the median 
duration of first line therapy was 185 days for BORT-based treatment and 250 days for LEN-
based treatment. Log-rank test results indicate that the duration of treatment for first line LEN-
based treatment was significantly greater than that for first line BORT-based treatment 
(p<0.001). The median all-cause survival was 1,558 days for the BORT-based treatment group 
and 1,545 days for the LEN-based treatment group. There were no significant differences in 
overall survival between the two groups (log-rank test: p > 0.050). Furthermore, median time to 
cardiotoxicity for the BORT-based treatment group was 609 days, and that for the LEN-based 
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treatment group was 516 days. There were no significant differences in time to cardiotoxicity 
between the two groups (log-rank test: p = 0.648). Additionally, median time to any adverse 
event for the BORT-based treatment group was 486 days, and that for the LEN-based group was 
417 days. There were no significant differences in time to any adverse event between the two 
groups (log-rank test: p = 0.813). Median time to thrombocytopenia and neutropenia could not be 
assessed for the two groups, since less than 25% of the patients in the two groups had these 
events. However, the mean time to event for these events were not significantly different 
between the two groups (thrombocytopenia: p = 0.989; neutropenia: p = 0.470).  
 Table 1.4 provides a descriptive summary of adverse events experienced by elderly 
NDMM patients while on first line LEN- and BORT-based treatment. 36.5% of the patients on 
BORT-based treatment had cardiotoxicity as compared to 42.2% of  those on LEN-based 
treatment. 3.9% and 4.7% of the patients had thrombocytopenia while on BORT- and LEN-based 
treatment respectively. The proportion of patients having neutropenia was 4% and 5.5% among 
those who received BORT- and LEN-based treatment respectively. Nearly 41% of the patients in 
BORT-based treatment group had any adverse event as compared to 46% of the patients in LEN-
based treatment group. No patients, in either of the two treatment groups, had tumor lysis 
syndrome while on first line treatment.   
 For each of the Cox proportional hazards regression models to compare survival and 
safety between first line LEN-based and BORT-based treatments, we tested the validity of the 
proportional hazards assumption by checking interactions with time and Schoenfeld residuals. 
Results of the validity of proportional hazards assumption are presented in Table 1.5. 
Statistically significant results imply violation of the proportional hazards assumption. As we can 
see, the proportional hazards assumption was violated for models for cardiotoxicity and the 
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composite any adverse event outcome. For both these models, the proportional hazards 
assumption was violated for the prior history of cardiotoxicity variable. For these two models, 
stratified Cox proportional hazards regression models with robust variance estimators were 
employed, stratified on the prior cardiotoxicity variable.  
 Results of the Cox proportional hazards models comparing survival and safety outcomes 
between the first line LEN-based and BORT-based treatment groups are presented in Table 1.6. 
As compared to first line LEN-based treatment, first line BORT-based treatment was associated 
with significantly greater hazard for all-cause death [hazard ratio (HR): 1.21, 95% Confidence 
Interval (CI): 1.01-1.47, p = 0.046]. There were no statistically significant differences between 
the two groups on any of the safety outcomes [cardiotoxicity: HR=0.94, 95% CI: 0.81-1.08; 
thrombocytopenia: HR=0.79, 95% CI=0.51-1.22; neutropenia: HR: 0.87, 95% CI=0.57-1.30; 
composite any adverse event: HR=0.93, 95% CI=0.82-1.06].  
Discussion 
In this study, we assessed the treatment patterns of continuous or maintenance treatment among 
elderly NDMM patients and compared the effective and safety of first line LEN-based vs BORT-
based continuous or maintenance treatment. To our knowledge, this is the first study to have 
assessed patterns of continuous or maintenance therapy in a population-based sample of elderly 
NDMM patients enrolled in fee-for-service Medicare. Moreover, while evidence from both 
clinical trials and observational studies have demonstrated clinical benefit of first line treatment 
with both LEN- and BORT-based regimens, this is the first head-to-head comparison between 
first line LEN- vs BORT-based continuous or maintenance treatment regimens in elderly 
NDMM patients. These results could help clinicians choose the most appropriate first line 
treatment for elderly NDMM patients.  
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 We found that 55.5% of the elderly MM patients receive first line LEN- or BORT-based 
treatments. The proportion of patients receiving BORT-based or LEN-based treatments as 
second line and third line therapies decreased to 46.0% and 42.5% respectively. Use of treatment 
regimens containing two or more novel anti-MM agents increased from 13.7% in the first line to 
around 24% in the second and third lines of treatment. These findings are similar to those of 
previous studies. A study that assessed treatment patterns among commercially insured MM 
patients found that nearly 60% of the patients received first line treatment with an IMID 
(lenalidomide or thalidomide) or PI (bortezomib) (MacEwan et al. 2018). As seen in our study, 
use of combination products of two or more novel anti-MM treatments increased as patients 
progressed from receiving only first line treatment to subsequent lines of treatment (second or 
third line of treatment). This is potentially because, as disease progresses, patients advance to 
next line of treatment, combination treatment regimens may be beneficial by targeting multiple 
pathways simultaneously without increasing the toxicity risk (Song, Cong, and Wilson 2016).  
 Additionally, we found that elderly NDMM patients who received first line LEN-based 
treatment had a longer TTNT as compared to those who received first line BORT-based 
treatment. While the median TTNT observed for our study sample was much shorter than those 
reported in clinical trials for first line LEN treatment (FIRST) and first line BORT treatment 
(VISTA), our findings were directionally consistent with that of the clinical trials (Benboubker et 
al. 2014; San Miguel et al. 2013). The shorter median TTNT for the two treatment groups in our 
study could possibly be explained by the fact that our study sample consisted of older and sicker 
patients with more frailty and worse functional status as compared to those in clinical trials. It 
has been seen that patients in clinical trials are often healthier than those in the real world, as 
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elderly patients with multi-morbidity, frailty and disability are often excluded from clinical trials 
(Hutchins et al. 1999; Huang et al. 2018).  
 In this study, we also found that compared to elderly NDMM patients who received first 
line LEN-based treatment, those who received first line BORT-based had significantly greater 
hazards for all-cause mortality. This finding is similar to the results  of a recent network meta-
analysis making direct comparisons between MM patients receiving LEN- and BORT-based 
maintenance therapy (Gay et al. 2018). Subgroup analysis among patients receiving SCT and 
taking prognostic factors (cytogenetic risk) also yielded similar results (Gay et al. 2018). On the 
other hand, one real-world study showed that the overall survival between LEN- and BORT-
based maintenance treatment was not significantly different (Huang et al. 2018). But this was a 
single center study with  a low sample size (Huang et al. 2018) Moreover, this retrospective 
study had a relatively short follow-up period, which may explain the lack of significant 
differences between the two groups (Huang et al. 2018).  In terms of comparative safety, we did 
not find significant differences between MM patients receiving first line LEN- and BORT-based 
continuous or maintenance therapy on any of the adverse events of interest or the composite 
adverse event outcome. These findings are consistent with results of a previous study comparing 
the risk of cardiotoxicity among commercially insured and Medicare Advantage MM patients 
receiving LEN- and BORT-based treatment. (Reneau et al. 2017). No other study has directly 
compared the occurrence of adverse events common to both treatments.   
 Out study has several strengths. First, we used a population-based cohort of elderly 
NDMM patients to assess treatment patterns, and compared the overall survival and safety of the 
two treatment options that are approved for as first line continuous or maintenance therapy of 
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elderly MM patients. Additionally, the rich information such as MM diagnosis data in the SEER 
registry made it possible for us depict patients’ clinical  journey from their initial MM diagnosis  
Our study has a number of limitations. First, our study sample consisted of elderly 
NDMM patients enrolled in fee-for-service Medicare. Hence, the results from our may not be 
generalizable to NDMM patients who are younger or elderly patients enrolled in Medicare 
Advantage plans. Second, as with other analysis involving administrative claims data, coding 
errors in the data might bias our study results. Third, we measured treatment duration using the 
TTNT approach, which was based on the addition or change of treatment, and pre-defined 
treatment gap. This approach may lead to misclassification of treatment duration for patients who 
may have long drug holiday or who had inadequate response to prior treatment but without 
showing signs of disease progression  (Arikian et al. 2015). Fourth, when clinical decisions are 
made for treatment choice, several clinical factors including cancer stage, disease prognosis, and 
functional status will be taken into consideration However, these factors are not available in the 
SEER-linked Medicare data used in this study. Future studies should take cancer staging, disease 
prognosis, and functional status into account while comparing safety and survival between 
various treatments.  
Conclusion 
This study used a population-based cohort of elderly NDMM patients to depict treatment 
patterns and assess the comparative safety and effectiveness among those who received first line 
LEN-based treatment versus those who received first line BORT-based treatment. Our study 
results corroborated that with several novel MM agents coming onto the market in the past 10 
years, MM treatment has seen a dynamic shift, with novel agents firmly established as the 
standard of care. We have found that the majority of the elderly NDMM patients received first 
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line novel agent-based therapy, and the uptake of combination MM agents in subsequent lines of 
therapy has been rising. Additionally, our study demonstrates an overall survival benefit and 
similar toxicity risk for patients receiving first line LEN-based continuous or maintenance 
treatment over those who received first line BORT-based treatment. This information is valuable 
for clinicians to make treatment decisions for elderly MM patients.    
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Table 1.1 Demographic and clinical characteristics of elderly NDMM patients, 2007-2016 
 
Demographic and Clinical 
Characteristics 
Category All Subjects 
n = 6,343 
Living in urban areas (n, %) No 733 11.6% 
Yes 5,610 88.4% 
Geographical region (n, %) Northeast 1,272 20.1% 
South 1,743 27.5% 
Midwest 814 12.8% 
West 2,514 39.6% 
Gender (n, %) Male 2,978 46.9% 
Female 3,365 53.1% 
Race (n, %) White 4,709 74.2% 
African American 1,009 15.9% 
Hispanic 190 3.0% 
Other 435 6.9% 
Charlson Comorbidity Index score 
category (n, %) 
0 1,475 23.2% 
1 1,298 20.5% 
2 945 14.9% 
3+ 2,625 41.4% 
Age category (n, %) 66-69 1,198 18.9% 
70-74 1,659 26.2% 
75-79 1,410 22.2% 
80-84 1,104 17.4% 
85+ 972 15.3% 
Disability status (n, %) No 4,871 76.8% 
Yes 1,472 23.2% 
Marital Status at diagnosis (n, %) Single 588 9.3% 
Married 3,103 48.9% 
Separated/Divorced 567 8.9% 
Widowed 1,615 25.5% 
Other 470 7.4% 
No 5,842 92.1% 
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Received Stem Cell Transplant (n, 
%) Yes 501 7.9% 
Treatment Line of Therapy (n, %)  0 1,095 17.3% 
  1 2,240 35.3% 
  2 1,326 20.9% 
  3 789 12.4% 
  4 or more 893 14.1% 
 
  
 
4
9
 
Table 1.2 Patterns of continuous or maintenance treatment among elderly NDMM patients, 2007-2016 
Variable 
Line of Therapy 1 
(n = 5,248) 
Line of Therapy 2 
(n = 3,008) 
Line of Therapy 3  
(n = 1,682) 
Regimen n % Regimen n % Regimen n % 
Treatment  BORT-based 
only 1,737 33.1% 
BORT-based 
only 755 25.1% 
BORT-based 
only 414 24.6% 
LEN-based only 1,173 22.4% LEN-based only 629 20.9% LEN-based only 301 17.9% 
THAL-based 
only 325 6.2% 
THAL-based 
only 114 3.8% 
THAL-based 
only 36 2.1% 
Combination 
drugs 718 13.7% 
Combination 
drugs 728 24.2% 
Combination 
drugs 406 24.1% 
Other 1,295 24.6% Other 782 26.0% Other 525 31.3% 
Duration of 
Therapy (Median, 
IQR), in days 
  195 
118, 
360 
  194 
113, 
352 
  168 
109, 
303 
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Table 1.3 Clinical and sociodemographic characteristics of elderly NDMM patients receiving first line BORT-based treatment 
matched with elderly NDMM patients receiving first line LEN-based treatment, 2007-2016 
Demographic and Clinical 
Characteristics 
Category BORT group 
 (n = 1,022) 
LEN group 
 (n = 1,022) 
Standardized 
Mean 
Difference 
p 
Living in urban areas (n, %) No 114 11.2% 110 10.8% 
0.013 0.747 
Yes 908 88.8% 912 89.2% 
Geographical region (n, %) Northeast 179 17.5% 194 19.0% 
0.041 0.653 
South 273 26.7% 264 25.8% 
Midwest 128 12.5% 123 12.0% 
West 442 43.3% 441 43.2% 
Gender (n, %) Male 475 46.5% 466 45.6% 
0.018 0.554 
Female 547 53.5% 556 54.4% 
Race (n, %) White 791 77.4% 775 75.8% 
0.077 0.259 
African American 138 13.5% 144 14.1% 
Hispanic 17 1.7% 28 2.7% 
Other 76 7.4% 75 7.4% 
Charlson Comorbidity Index score 
category (n, %) 
0 263 25.7% 258 25.2% 
0.033 0.735 
1 234 22.9% 223 21.8% 
2 140 13.7% 144 14.1% 
3+ 385 37.7% 397 38.9% 
Age category (n, %) 66-69 159 15.6% 148 14.5% 
0.047 0.64 
70-74 285 27.9% 276 27.0% 
75-79 244 23.9% 244 23.9% 
80-84 199 19.5% 212 20.7% 
85+ 135 13.1% 142 13.9% 
Disability status (n, %) No 816 79.8% 798 78.1% 
0.043 0.221 
Yes 206 20.2% 224 21.9% 
Marital Status (n, %) Single 93 9.1% 99 9.7% 0.04 0.831 
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Married 542 53.0% 522 51.1% 
Separated/Divorced 70 6.9% 73 7.1% 
Widowed 241 23.6% 248 24.3% 
Other 76 7.4% 80 7.8% 
Received Stem Cell Transplant (n, 
%) 
No 985 96.4% 985 96.4% 
<0.001 > 0.999 
Yes 37 3.6% 37 3.6% 
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Table 1.4 Summary of adverse events for patients receiving first line BORT-based vs first 
line LEN-based treatment among elderly NDMM patients, 2007-2016 
 
Adverse Events Category BORT group 
 (n = 1,022) 
LEN group 
 (n = 1,022) 
Cardiotoxicity (n, %) No 649 63.5% 591 57.8% 
Yes 373 36.5% 431 42.2% 
Thrombocytopenia (n, %) No 982 96.1% 974 95.3% 
Yes 40 3.9% 48 4.7% 
Neutropenia (n, %) No 981 96.0% 966 94.5% 
Yes 41 4.0% 56 5.5% 
Tumor Lysis Syndrome (n, %) No 1,022 100.0% 1,022 100.0% 
Yes 0 0.0% 0 0.0% 
Any Adverse Event (n, %) No 607 59.4% 549 53.7% 
Yes 415 40.6% 473 46.3% 
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Table 1.5 Tests for validity of proportional hazards assumption for overall survival and 
adverse event outcomes  
Outcome Variable Interaction 
with time 
Schoenfeld Residual 
time log(time) time*time 
All-cause death Treatment Group  0.659 0.521 0.146 0.832 
Cardiotoxicity Treatment Group  0.243 0.241 0.06 0.562 
Prior Cardiac 
Toxicity <0.001 <0.001 <0.001 0.003 
Thrombocytopenia Treatment Group  0.729 0.994 0.465 0.941 
Prior 
Thrombocytopenia 0.262 0.292 0.135 0.385 
Neutropenia Treatment Group  0.686 0.729 0.096 0.846 
Prior Neutropenia 0.221 0.239 0.162 0.249 
Any adverse event 
(composite) Treatment Group  0.287 0.218 0.105 0.555 
  
Prior Cardiac 
Toxicity <0.001 <0.001 <0.001 0.003 
  
Prior 
Thrombocytopenia 0.742 0.244 0.237 0.243 
  Prior Neutropenia 0.746 0.348 0.128 0.681 
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Table 1.6 Cox proportional hazards regression analysis comparing overall survival and 
safety between first line BORT-based and LEN-based treatments among elderly NDMM 
patients, 2007-2016  
Outcome Treatment 
Group 
Hazard 
Ratio 
95%  
LCL 
95%  
UCL 
p 
All-cause Death BORT 1.21 1.01 1.47 
0.046 
LEN Ref Ref Ref 
Cardiotoxicity BORT 0.94 0.81 1.08 
0.361 
LEN Ref Ref Ref 
Thrombocytopenia BORT 0.79 0.51 1.22 
0.289 
LEN Ref Ref Ref 
Neutropenia BORT 0.87 0.57 1.3 
0.488 
LEN Ref Ref Ref 
Any adverse event 
(composite) 
BORT 0.93 0.82 1.06 
0.291 
LEN Ref Ref Ref 
 
 
 55 
 
 
 
 
 
 
 
 
 
APPENDIX B 
  
 56 
 
Figure 1.1 Kaplan-Meier survival plot for treatment duration for elderly NDMM patients 
receiving first line BORT-based vs LEN-based treatment 
 
 
 
 
 
Treat_grp: 0 indicates BORT-based treatment; 1 indicates LEN-based treatment 
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Figure 1.2 Kaplan-Meier survival plot for overall survival for elderly NDMM patients 
receiving first line BORT-based vs LEN-based treatment 
 
 
 
 
  
Treat_grp: 0 indicates BORT-based treatment; 1 indicates LEN-based treatment 
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Figure 1.3 Kaplan-Meier survival plot for cardiotoxicity for elderly NDMM patients 
receiving first line BORT-based vs LEN-based treatment 
 
 
 
 
  
Treat_grp: 0 indicates BORT-based treatment; 1 indicates LEN-based treatment 
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Figure 1.4 Kaplan-Meier survival plot for thrombocytopenia for elderly NDMM patients 
receiving first line BORT-based vs LEN-based treatment 
 
 
 
 
  
Treat_grp: 0 indicates BORT-based treatment; 1 indicates LEN-based treatment 
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Figure 1.5 Kaplan-Meier survival plot for neutropenia for elderly NDMM patients 
receiving first line BORT-based vs LEN-based treatment 
 
 
 
 
  
Treat_grp: 0 indicates BORT-based treatment; 1 indicates LEN-based treatment 
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Figure 1.6 Kaplan-Meier survival plot for the composite any adverse event outcome for 
elderly NDMM patients receiving first line BORT-based vs LEN-based treatment 
 
 
 
 
Treat_grp: 0 indicates BORT-based treatment; 1 indicates LEN-based treatment 
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CHAPTER 3: PAPER 2 
Disease Lifetime Costs and its Predictors among Elderly Patients Newly Diagnosed with 
Multiple Myeloma 
Introduction 
Multiple Myeloma (MM) is a hematologic malignancy characterized by abnormal growth of 
clonal plasma cells. It is diagnosed based on presence of 10% or more clonal plasma cells on 
bone marrow examination, and monoclonal protein in serum or urine. Diagnosis of symptomatic 
MM requires proof of end organ damage, and is defined as presence of one or more of the 
following diseases – hypercalcemia, renal insufficiency, anemia, and bone disease (Palumbo 
2012; International Myeloma Working Group 2003). In the United States (US), around 1.6% of 
all new cancer cases can be attributed to MM, and it has a lifetime risk of 1 in 132 (Chen et al. 
2017; American Cancer Society 2018). As per the latest incidence and mortality statistics, an 
estimated 30,770 new cases of MM and 12,770 deaths from MM were reported in the US in 
2018 (Siegel, Miller, and Jemal 2018). The median age at MM diagnosis is approximately 66-70 
years, with 63% of the diagnosed patients being 65 years of age or older (Kazandjian 2016).        
 MM treatment has seen a paradigm shift in the past few decades, first with the 
development of autologous stem cell transplant (ASCT), and then with the approval of novel 
agents, such as immunomodulatory drugs (IMIDs) - thalidomide and lenalidomide, and 
proteasome inhibitor (PI) bortezomib in the 2000s. The introduction of ASCT and novel agents 
have led to drastic changes in MM management, and prolonged overall survival (Kristinsson et 
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al. 2007; Brenner, Gondos, and Pulte 2008; Kumar et al. 2008). Moreover, the last few years 
have seen even more modifications in the treatment landscape for MM with approvals of IMID 
pomalidomide in 2013, PIs carfilzomib and ixazomib in 2012 and 2015 respectively, and 
monoclonal antibodies daratumumab and elotuzumab in 2015 (Fonseca et al. 2017).  
Cost associated with cancer treatment poses a significant burden to patients and their family 
members, payers, and society in general. The estimated total direct medical costs attributable to 
cancer treatment in the US was around $125 billion in 2010 (Roy et al. 2015). Even though MM 
accounts for a small proportion of patients with cancer, healthcare costs associated with 
treatment of MM  are higher than treatment of most other types of cancer (Cook 2008).  While 
real-world studies have assessed healthcare expenditures among MM patients, most of these 
studies have been limited to assessment of healthcare costs in various lines of treatment (e.g., 
first-line vs second-line) or examination of treatment-related costs (novel agent use versus other 
therapy) (MacEwan et al. 2018; Arikian et al. 2015; Teitelbaum et al. 2013). Very few studies 
have assessed disease-related costs. One such study that assessed trends in healthcare 
expenditure among newly diagnosed multiple myeloma (NDMM) patients with commercial 
insurance and private Medicare supplemental coverage between 2000 and 2014 in the US found 
that there was a three-fold increase in total per patient per month (PPPM) healthcare costs 
between 2000 and 2014 ($3,263 in 2000 vs $14,656 in 2014). Outpatient services and 
hospitalizations were reported to be the major drivers of the increase in costs. The study also 
compared total all-cause costs among MM patients and matched controls between 2000 and 
2014, and found that the PPPM all-cause costs increased 476% for MM patients as compared to 
182% for the matched controls (Fonseca et al. 2017). A cost of illness (COI) analysis among 
MM patients during one year of disease management in Italy, reported a total COI of €19,267, 
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with drug costs and hospital admissions being the primary drivers of total COI (Petrucci et al. 
2013). Another analysis of healthcare costs among MM patients, conducted in Italy from a 
hospital perspective, reported annual costs of €14,053 (Koleva et al. 2011), whereas a Swedish 
chart review study conducted over a period of 5 years reported a mean PPPM cost of €2,770 for 
MM patients (Ghatnekar et al. 2008). 
 Most of the studies that have assessed disease-related costs in MM have used a 
prevalence-based approach. It is important to assess healthcare expenditures across phases of 
MM care. This is due to the fact that as disease progresses, treatments differ and thus, costs differ 
by each phase of MM care (de Oliveira et al. 2016). Extant literature on healthcare costs among 
cancer patients suggest that healthcare expenditures across the disease continuum follows a U-
shaped curve, with greater expenditure incurred around the time of diagnosis (initial care phase) 
and death (terminal phase), and lower expenditures incurred in the continuing care phase 
between the initial care phase and the terminal phase. These studies have also shown that such 
phase-based cost estimates in combination with survival estimates yield reliable estimates of 
long-term disease burden (Brown et al. 1999; 2002; de Oliveira et al. 2013; Krahn et al. 2010; 
Yabroff et al. 2008). Assessment of phase-specific costs provides a natural framework for 
analysis of disease lifetime costs across the entire care continuum among cancer patients. While 
the initial phase costs reflect the costs of initial course of diagnosis and therapy, continuing care 
phase costs provide an estimate of the economic burden of surveillance and maintenance costs 
post the initial care phase. Terminal phase costs are reflective of costs incurred at the end of life 
(R. Etzioni et al. 2002). A better understanding of healthcare costs across various phases of 
cancer care and the drivers of these costs would help plan interventions and policy decisions 
targeted towards improving quality of cancer care while controlling costs (Kaye et al. 2018).          
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 However, there is very limited literature on disease lifetime costs of MM. One study, 
conducted using data from the Ontario Cancer Registry reported that the costs of MM patients 
were higher in the initial care phase ($24,447 for males, and $24,052 for females) and terminal 
phase ($43,989 for males, and $45,871 for females), and lower in the continuing care phase 
($15,153 for males, and $15,255 for females) and pre-diagnosis period ($3,142 for males, and 
$2,609 for females). This study also found that MM has the highest disease lifetime costs  among 
of all types of cancer (de Oliveira et al. 2016). Given that majority of the MM patients in the US 
are diagnosed at an age of 65 or greater, and that Medicare is the primary payer for this 
population, and taking into consideration the changing landscape of MM treatment with 
introduction of several novel agents, it is important to assess the disease lifetime costs of MM 
from Medicare’s perspective. However, no study in the US has yet evaluated the disease lifetime 
costs of MM from Medicare’s perspective. 
One difficulty in the assessment of disease lifetime costs is defining the duration of the various 
phases of care, which varies based on the type of cancer and cancer stage at diagnosis. While 
studies among patients with breast cancer and pancreatic cancer have defined duration of the 
terminal phase as 12 months prior to death, for patients with metastatic colorectal cancer, it has 
been defined as 3 months prior to death (Brown et al. 2002; Seidler et al. 2010; Chang et al. 
2006; Paramore et al. 2006). In majority of incidence-based approaches for cost estimation, the 
first 6 months post diagnosis is defined as the initial phase of care, and the last 12 months before 
death as the terminal phase, with the time between the first 6 months and the last 12 months 
defined as the continuous phase. However such an assignment of phases of care is mostly 
arbitrary. Thus, it would be ideal to establish a data-driven approach that, in conjunction with 
clinical judgement, to establish a benchmark for defining phases of MM care, consistent with 
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extant phase-based net cost and disease lifetime cost literature in other cancers (Atkins et al. 
2018).  
In the current study, we aimed to determine the duration of initial phase and terminal phase for 
elderly NDMM patients using a data driven approach, assess phase-specific costs and disease 
lifetime costs of MM compared to matched non-cancer group, and to identify drivers of MM 
costs for each phase among elderly newly diagnosed MM patients.  
Methods 
Study Design and Data Source  
A retrospective analysis was conducted using National Cancer Institute’s (NCI) SEER database 
linked with Medicare administrative claims database. The NCI’s SEER program is an 
epidemiologic surveillance system that contains data collected from population-based tumor 
registries and was designed to track cancer incidence and mortality in the US. It includes clinical 
and demographic information in addition to information on cause of death for people with 
cancer, and is collected from 18 participating cancer registries across the US. Medicare is a 
federally administered health insurance program which covers elderly Americans who are 65 
years of age or older, as well as younger patients with disabilities and end-stage renal disease 
(ESRD). The Medicare administrative claims database provides information on claims for 
covered healthcare services for beneficiaries enrolled in Medicare. The SEER-linked Medicare 
claims database provides patient-level data for Medicare beneficiaries with cancer (Warren et al. 
2002).  
The current study has been approved by the University of Mississippi’s Institutional 
Review Board (IRB), and utilized 2007-2015 SEER data linked with 2006-2016 Medicare claims 
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data. The SEER data consists of the Patient Entitlement and Diagnosis Summary File (PEDSF) 
that includes clinical, demographic, and Medicare enrollment information for individuals with 
cancer. The Medicare claims data consists of the Medicare Provider Analysis and Review 
(MEDPAR), National Claims History (NCH), Outpatient (OUTPT), Home Health Agency 
(HHA), Hospice, Durable Medical Equipment (DME), and Prescription Drug Event (PDE) files. 
The MEDPAR file contains all Medicare Part A claims indication short stay, long stay, skilled 
nursing facility (SNF) stays as well as ICD-9/10 diagnoses and procedures performed during 
each stay. The NCH file contains all Medicare Part B claims generated due to physician or 
supplier services in clinics and hospitals, whereas the OUTPT file contains all Medicare Part B 
claims outpatient providers. Both NCH and OUTPT files was used to obtain information such as 
procedural Healthcare Common Procedure Coding System (HCPCS) codes, diagnoses, date of 
claims, treatment administration, and reimbursement amounts. The HHA file contains claims for 
all home health care services such as number and types of visits and diagnoses. The hospice file 
contains claims submitted by hospice providers, and has details on type of care (inpatient care, 
routine home care) as well as terminal diagnosis associated with that care. The DME file 
contains claims with information on use of oral and intravenous chemotherapy, and infusion 
pumps used. The PDE file contains information about drug utilization such as, date of 
prescription fill, drug dispensed, quantity dispensed, days supplied, total cost, and out-of-pocket 
cost.  
Study sample 
This study included Medicare beneficiaries who entered the SEER registry from 2007 through 
2015, and were diagnosed with MM as primary cancer. All beneficiaries with primary MM were 
identified based on the International Classification of Diseases for Oncology, 3rd Edition (ICD-
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O-3) code of MM (9732). MM patients needed to be 66 years of age or older at the time of MM 
diagnosis and have continuous enrollment in Medicare Parts A, B, and D for at least two months 
post-MM diagnosis or until death to be included in the study. Non-cancer Medicare beneficiaries 
in the 5% random sample were included as the control group. Non-cancer controls were included 
if they were 65 years of age or older and were continuously enrolled in Medicare Parts A, B, and 
D for at least 14 months from the month of start of Medicare eligibility or until death. MM 
patients were excluded from the study sample if they had an unknown diagnosis month or year, 
if MM diagnosis was made at the time of death, if they had any cancer in the 5 years prior to 
MM diagnosis, and if they were enrolled in a health maintenance organization (HMO) at any 
time between 12 months prior to MM diagnosis and death or end of study period. Beneficiaries 
in the non-cancer group will also be excluded if they were enrolled in a HMO at any time during 
the study period.  
Medicare beneficiaries in the MM group and non-cancer group were matched 1:1 on 
months of Medicare eligibility and death date (for those who died) / date of loss of Medicare 
eligibility or end of study (for those who did not die during the follow-up period), using a greedy 
matching algorithm. Beneficiaries in the non-cancer cohort were assigned the MM-diagnosis 
date of the matched MM beneficiary.       
Study variables 
The outcome variable of interest is all-cause healthcare cost. We used payments made by 
Medicare (as opposed to all sources of payments or any charge variables) when making 
monetary comparisons. All cost estimates were adjusted to 2016 US dollars using the Medical 
Care Component of the Consumer Price Index.  
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 For assessment of disease lifetime costs, ideally all beneficiaries (cases and controls) 
should be followed until death. However, due to short study horizons, death may not be observed 
for all beneficiaries. For those who did not die during the study observation period, a portion of 
their healthcare costs remain unobserved, leading to right censoring of healthcare costs due to 
which their observed costs underrepresent their actual costs (Huang 2009). For such an analysis, 
we can either use a full-sample estimator (irrespective of whether the beneficiary died or was 
censored) or use an uncensored case estimator (which only considers those beneficiaries that 
died during the observation period). Since the full sample estimator would only include a portion 
of the costs for censored beneficiaries, it would lead to an underestimation of the actual costs 
(Bang 2005). For the uncensored case estimator, only those beneficiaries that died during the 
study observation period is considered. However, the probability of remaining uncensored is not 
the same at all time points. As time increase, the probability of being uncensored decreases. 
Hence, the uncensored case estimator would be biased towards those beneficiaries that died early 
(Bang 2005; Raikou and McGuire 2004).  
 Reweighted estimators can be used to estimate mean healthcare costs for censored data. 
Various reweighted estimators (Lin 1997 estimator, simple IPW estimator, partitioned extension 
of the simple IPW estimator) have been developed over time using Kaplan-Meier (K-M) 
techniques (Wijeysundera et al. 2012). But use of these estimators to estimate lifetime costs may 
lead to biased estimates (Huang 2009; Austin, Ghali, and Tu 2003; R. D. Etzioni et al. 1999; 
Lipscomb et al. 1998). Since independent censoring is a requirement for K-M survival curves, it 
require time to censoring to be independent of time to death. But the lifetime cost to censoring 
for a beneficiary will not independent from their lifetime cost to death, since both are related to 
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the beneficiary’s cost accumulation pattern (Huang 2009; Austin, Ghali, and Tu 2003; R. D. 
Etzioni et al. 1999; Lipscomb et al. 1998).   
 In light of the limitations associated with use of reweighted estimators, phase-based 
modeling approach is an alternative method for estimating lifetime costs. Since actual lifetime 
costs for the cohort does not need to be observed in the phase-based modeling approach, it does 
not suffer from the limitations that affect the IPW methods (Brown et al. 1999; R. Etzioni et al. 
2002; Wijeysundera et al. 2010; Yabroff et al. 2009). This method has been used by several 
studies to estimate lifetime costs of cancer (Yabroff et al. 2009; 2005).         
Consistent with previous studies that have employed a phase-based approach to model 
healthcare costs, costs were divided into four phases – 1) pre-diagnosis phase, which is defined 
as 3 months prior to diagnosis (Christensen et al. 2012; Hornbrook et al. 2013), 2) initial phase, 
3) continuing phase, and 4) terminal phase (Brown et al. 1999; Yabroff et al. 2008; Baker et al. 
1991; Taplin et al. 1995). Duration of the initial phase and terminal phase was determined using 
a data driven approach (joinpoint analysis) (Atkins et al. 2018; Kim et al. 2000). For each phase-
specific cost, cost attributable to MM was calculated by subtracting the costs incurred by cases 
from those incurred by matched controls, using the net cost method (de Oliveira et al. 2016; 
Brown et al. 1999; Taplin et al. 1995).     
Baseline demographic covariates included age (at MM diagnosis), sex, race, geographic 
location, and urban residency. Baseline clinical covariates included comorbidity, and disability 
status. Comorbidity was assessed using the Deyo adaption of the Charlson Comorbidity Index 
(CCI) (Deyo, Cherkin, and Ciol 1992). Disability status, which is a proxy measure for 
performance status, was calculated using a validated, claim-based algorithm during the 12-month 
baseline period prior to MM diagnosis (Davidoff et al. 2013).  
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Analysis 
Descriptive statistics were used to depict baseline patient characteristics, and costs. For 
categorical variables, frequency and percentage distributions were reported. Statistical 
comparisons were conducted between the groups using McNemar’s test or Cochrane-Mantel-
Haenszel test, to account for the matched data. For continuous variables, mean, standard 
deviation (SD), median, and range were reported. Statistical comparisons for continuous 
variables were conducted using paired t-tests. For unadjusted healthcare costs, Wilcoxon signed 
rank tests were used to test for significant differences between the groups.   
Determination of duration of initial phase and terminal phase 
Joinpoint regression analysis was performed using Joinpoint regression software, developed by 
the Surveillance Research Program of the National Cancer Institute to identify duration of initial 
and terminal phases for MM patients. For this analysis, all MM patients in the sample who died 
before the end of study period were considered.   
Joinpoint regression is a piecewise linear regression used to identify the best-fitting 
points where statistically significant changes in the trends of monthly costs occur. Separate 
models were estimated for the initial phase and the terminal phase. The model selection 
parameters for the Joinpoint regression analyses were based on diagnostic tests for 
heteroscedasticity – using the Cook-Weisberg test for heteroscedasticity, and autocorrelation - 
using the Breusch-Godfrey LM test for autocorrelation. For the initial phase model, average 
monthly costs were modeled from MM diagnosis to death, and for the terminal phase model, 
costs were modeled backward from death to MM diagnosis. The study used a minimum of 0 
joinpoints to a maximum of 4 joinpoints to identify best fit of data (Kim et al. 2000). Joinpoints 
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were defined as points of inflection in the trend of monthly costs. The joinpoints were then used 
to estimate the duration of the initial and terminal phases. The months in between the initial and 
terminal phase were assigned to the continuing phase (Atkins et al. 2018). 
Estimation of Phase-based costs 
To estimate lifetime costs for MM using the phase-based approach, the cohort was divided into 
four phases – pre-diagnosis phase, initial phase, continuing phase, and terminal phase. Once the 
duration of the various phases have been determined, time (in months) spent and costs in each 
phase were calculated for the entire cohort. Upon calculation of monthly costs for the entire 
cohort, mean cost per phase were assessed, and then disease lifetime costs were assessed using 
phase-specific cost data and time to death data. Mean cost per phase were estimated by 
multiplying the phase-specific costs to the survival function estimates (Wijeysundera et al. 
2012).  
 Beneficiaries, who died during the post-diagnosis observation period, were first be 
assigned to the terminal phase. Once they had been assigned to the terminal phase, any 
remaining time spent was first assigned to the initial phase, and then to the continuing phase. 
Beneficiaries, who did not die during the post-diagnosis observation period, were first assigned 
to the initial phase and then to the continuing phase (Wijeysundera et al. 2012).    
All costs attributable to MM (lifetime, phase-specific, and individual medical service 
component costs within each phase) were estimated controlling for clinical and socio-
demographic characteristics at baseline. Generalized linear models with log link and gamma 
distribution were used to assess incremental MM costs, due to their advantage over other models 
with regards to re-transformation bias and heteroscedasticity (Gregori et al. 2011; Mihaylova et 
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al., n.d.). In order to account for covariate imbalance, recycled prediction technique was used to 
assess the incremental impact of MM for all the cost outcomes (A. Basu and Rathouz 2005; 
Anirban Basu, Polsky, and Manning 2011). For this technique, the outcome was first predicted 
assuming every recipient to be in the non-cancer group, and then the outcome was again 
predicted assuming every recipient to be in the MM group. The incremental impact was then 
assessed by calculating the difference between the predicted outcomes for the MM and non-
cancer groups. Percentile bootstrapping with 2000 replications was conducted to compute the 
95% Confidence Interval (CI) for each outcome. All statistical analyses were conducted using 
NCI’s Joinpoint regression software, SAS version 9.4, and STATA 15.  
Results 
6,151 NDMM patients and 111,736 non-cancer beneficiaries met the study inclusion and 
exclusion criteria. Of the 6,151 beneficiaries in the MM group, 3,651 died during the study 
period. Monthly cost data for these 3,651 NDMM patients was utilized for the Joinpoint 
regression analyses to determine the duration of the initial and terminal care phases. Based on the 
results of the Cook-Weisberg test for heteroscedasticity and Breusch-Godfrey LM test for 
autocorrelation, a heteroscedastic, autocorrelated model was used for estimating duration of both 
initial and terminal phases. As mentioned in the study methodology, the 3 months prior to MM 
diagnosis was considered as the pre-diagnosis phase, and any time spent by the beneficiaries 
between the initial and terminal phases was assigned to the continuing care phase.  
 Joinpoint regression result for identifying duration of the initial phase showed statistically 
significant inflection points in monthly cost trends at month 4 [monthly percent change (MPC):  
-15.0%, 95% Confidence Interval (CI): (-17.7%) - (-12.2%)] and month 14 [monthly percent 
change (MPC): -2.7%, 95% CI: (-3.4%) – (-2.0%)]. Most of the studies that have assessed 
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lifetime and phase-specific costs in cancer have conventionally considered the first 6 months or 
12 months after diagnosis as the initial care phase (Banegas et al. 2018; Aly et al. 2018; Barlow 
2009; Deshmukh et al. 2018; Kaye et al. 2018; Lang et al. 2009). It is unlikely for the initial 
phase to span across the first 14 months after diagnosis, and no previous study has considered the 
initial phase to be more than 12 months. Furthermore, results of the Joinpoint regression analysis 
reported a comparatively small MPC for the inflection point at month 14. Considering all the 
information, the duration of the initial phase among elderly NDMM patients was identified as the 
4-month period post MM-diagnosis. 
 Joinpoint regression analysis result for identifying duration of the terminal phase showed 
statistically significant inflection points in monthly trend costs at month 3 prior to death 
[monthly percent change (MPC):  20.8%, 95% Confidence Interval: 17.3% - 24.1%], and month 
8 prior to death [monthly percent change (MPC):  6.9%, 95% Confidence Interval: 5.4% - 8.4%]. 
Based on these results, the duration of the terminal phase was identified as the 3-month period 
prior to death. In addition, sensitivity analysis was conducted using the 8-month period prior to 
death as the terminal phase.  
 For assessing the incremental lifetime and phase-specific costs of MM, 4,533 elderly, 
NDMM patients were matched to 4,533 non-cancer Medicare beneficiaries. As compared to the 
non-cancer group, a greater percentage of MM patients lived in a rural area (93.1% for the MM 
group vs 88.4% for the non-cancer group, p<0.001) and were males (47.6% for the MM group vs 
40.5% for the non-cancer group, p<0.001). A lower percentage of beneficiaries in the MM group 
were considered to have disability in the 12-month baseline period as compared to the non-
cancer group (19.1% vs 23.7%, p<0.001).  Moreover, statistically significant differences were 
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seen between the MM group and non-cancer group on their geographical region of residence 
(p<0.001), race (p<0.001), CCI score categories (p<0.001), and age at baseline (p<0.001).  
 The bivariate analysis results (Table 2.2) depict the significantly greater mean lifetime 
costs ($212,474 vs $54,086, p<0.001) for the MM group as compared to the matched non-cancer 
group. Moreover, beneficiaries in the MM group had significantly greater mean per member per 
month (PMPM) pre-diagnosis phase costs ($2,081 vs $1,567, p<0.001), initial phase costs 
($10,384 vs $1,618, p<0.001), continuing care phase costs ($6,083 vs $1,495, p<0.001), and 
terminal phase costs ($14,417 vs $8,853, p<0.001) as compared to the matched non-cancer 
group.  
In the pre-diagnosis phase (3 month prior to diagnosis), beneficiaries in the MM group 
had greater mean PMPM outpatient ($791 vs $396, p<0.001) and inpatient costs ($896 vs $733, 
p<0.001) as compared to their matched non-cancer counterparts. In the initial care phase, 
beneficiaries in the MM group had greater mean PMPM outpatient ($3,977 vs $432, p<0.001), 
inpatient ($3,685 vs $692, p<0.001), pharmacy ($2,369 vs $285, p<0.001), and other costs ($353 
vs $209, p<0.001) as compared to those in the non-cancer group. In the continuing care phase, 
beneficiaries in the MM group had greater mean PMPM outpatient ($1,998 vs $383, p<0.001), 
inpatient ($1,270 vs $667, p<0.001), pharmacy ($2,567 vs $237, p<0.001), and other costs ($248 
vs $207, p<0.001) as compared to their non-cancer counterparts. In the terminal phase, 
beneficiaries in the MM group had greater mean PMPM outpatient ($3,424 vs $1,404, p<0.001), 
inpatient ($7,845 vs $6,129, p<0.001), pharmacy ($1,847 vs $331, p<0.001), and other costs 
(home health agency, hospice, durable medical equipments) ($1,301 vs $989, p<0.001) as 
compared to those in the non-cancer group. As seen in Table 2.3, results of the sensitivity 
analysis using the 8-month period prior to death as terminal phase produced similar results.  
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Results of the multivariable analysis for assessing the incremental MM lifetime, phase-
specific, and medical service component (inpatient, outpatient, pharmacy, and other) costs within 
each phase controlling for clinical and sociodemographic covariates are presented in Table 2.4. 
The mean adjusted lifetime cost for the MM group ($234,002; 95% Confidence Interval [CI]: 
$232,232-$235,870) was significantly greater than that for the non-cancer group ($49,507, 95% 
CI: $49,133-$49,902), with an incremental expenditure of $184,495 (95% CI: $183,099-
$185,968).  
The mean adjusted pre-diagnosis phase PMPM cost for the MM group ($2,588, 95% CI: 
$2,531-$2,647) was significantly greater than that of their matched non-cancer counterparts 
($1,344, 95% CI: $1,314-$1,375), resulting in an incremental expenditure of $1,244 (95% CI: 
$1,216-$1,272). Within the pre-diagnosis phase, the incremental PMPM outpatient cost was 
$508 (95% CI: $501-$515), incremental PMPM inpatient cost was $704 (95% CI: $696-$713), 
incremental PMPM pharmacy cost was $21 (95% CI: $20-$21), and incremental PMPM other 
cost was $29 (95% CI: $28-$31).  
The mean adjusted initial phase PMPM cost for the MM group ($12,556, 95% CI: 
$12,412-$12,700) was significantly greater than that for the non-cancer group ($1,375, 95% CI: 
$1,360-$1,391), an incremental expenditure of $11,181 (95% CI: $11,052-$11,309). Within the 
initial phase, the incremental PMPM outpatient cost was $3,973 (95% CI: $3,943-$4,005), 
incremental PMPM inpatient cost was $4,275 (95% CI: $4,199-$4,350), incremental PMPM 
pharmacy cost was $2,237 (95% CI: $2,224-$2,252), and incremental PMPM other cost was 
$721 (95% CI: $697-$744).  
The mean adjusted continuing care phase PMPM cost for the MM group ($6,968, 95% 
CI: $6,897-$7,042) was significantly greater than that of their matched non-cancer counterparts 
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($1,334, 95% CI: $1,320-$1,348), an incremental expenditure of $5,634 (95% CI: $5,577-
$5,694). Within the continuing care phase, the incremental PMPM outpatient cost was $1,802 
(95% CI: $1,788-$1,816), incremental PMPM inpatient cost was $1,087 (95% CI: $1,074-
$1,101), incremental PMPM pharmacy cost was $2,526 (95% CI: $2,513-$2,540), and 
incremental PMPM other cost was $214 (95% CI: $208-$220). 
The mean adjusted terminal phase PMPM cost for the MM group ($15,364, 95% CI: 
$15,286-$15,447) was significantly greater than that for the non-cancer group ($9,084, 95% CI: 
$9,038-$9,133), an incremental expenditure of $6,280 (95% CI: $6,248-$6,314). Within the 
terminal phase, the incremental PMPM outpatient cost was $2,181 (95% CI: $2,168-$2,194), 
incremental PMPM inpatient cost was $2,060 (95% CI: $2,046-$2,075), incremental PMPM 
pharmacy cost was $1,600 (95% CI: $1,593-$1,608), and incremental PMPM other cost was 
$461 (95% CI: $457-$464). 
Results of the sensitivity analyses using the 8-month period prior to death as the terminal 
phase are presented in Table 2.5. As depicted in Table 2.5, the results for the sensitivity analyses 
are similar to that of the base case (3-month terminal phase).  
Discussion 
To the best of our knowledge, this is the first study to have used a data-driven approach to 
estimate the duration of initial and terminal care phases among elderly patients newly diagnosed 
with MM. It is also the first study to estimate the disease lifetime cost of MM from Medicare’s 
perspective. In the US, patients newly diagnosed with MM have a median age at diagnosis of 
around 69 years, and about 65% of the diagnosed MM patients are 65 years of age or older at the 
time of diagnosis (Kazandjian 2016). Since, Medicare is the primary payer for those who are 65 
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years or older, it is important to estimate the cost burden of MM from Medicare’s perspective. 
Furthermore, this study used a phase-based costing approach to estimate incremental costs for 
each phase of MM care – pre-diagnosis, initial, continuing care, and terminal, and drivers of 
these phase-specific costs were also identified. This information will inform resource allocation 
decisions, and aid policy makers and payers in devising innovative interventions targeted 
towards improving quality of MM care while staying within their budgets (Kaye et al. 2018).   
 Using a data-driven approach (Joinpoint regression), we determined the duration of the 
initial phase to be 4 months post MM diagnosis among Medicare beneficiaries. This is the first 
study to have assessed the duration of the initial care phase in a real-world cohort of MM 
patients. The convention in majority of the studies that have employed the phase-based costing 
approach to assess phase-specific costs among cancer patients, in general, is to consider the first 
6 or 12 months after diagnosis to be the initial phase (Banegas et al. 2018; Aly et al. 2018; 
Barlow 2009; Deshmukh et al. 2018; Kaye et al. 2018; Lang et al. 2009). However, such an 
allocation is often arbitrary and does not take into account the differences in care patterns for 
different cancer types. Some studies of phase-based estimates of costs of medical care in other 
cancer types have used similar data driven approaches to identify the duration of the initial 
phase. One such study, among metastatic melanoma patients, determined the duration of the 
initial phase to be 5 months post diagnosis of metastasis (Atkins et al. 2018). Another study, 
among newly diagnosed elderly melanoma patients in the US, estimated the duration of the 
initial phase to be the first 4 months post diagnosis (Seidler et al. 2010).     
For the terminal phase, we found a significant change in the monthly cost trends at the 3-
month and 8-month periods prior to death. No previous study has determined the duration of the 
terminal care phase in a real-world cohort of MM patients. The convention in most phase-based 
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costing studies in oncology has been to consider the last 12 months prior to death as the terminal 
phase (Banegas et al. 2018; Aly et al. 2018; Brown et al. 1999; Barlow 2009; Deshmukh et al. 
2018; Kaye et al. 2018; Lang et al. 2009). However, such an approach does not take into account 
variations in disease-specific care patterns in different cancer types. A few other studies have 
used data driven approaches, similar to ours, to identify duration of the terminal phase in various 
other cancer types. A study among metastatic melanoma patients estimated the duration of the 
terminal phase to be the last 5 months prior to death (Atkins et al. 2018). Another study, among 
elderly newly diagnosed melanoma patients assessed the duration of the terminal phase to be the 
last 6 months prior to death (Seidler et al. 2010). Moreover, the duration of the terminal phase 
was estimated to be the last 3 months prior to death in a cohort of newly diagnosed metastatic 
colorectal cancer patients (Paramore et al. 2006).  
Our study estimated the incremental disease lifetime cost of MM to be $184,494 for the 
base case, i.e., considering the 3-month period prior to death as the terminal phase. Sensitivity 
analysis with the terminal phase being the last 8 months prior to death produced similar results, 
with the estimated the incremental disease lifetime cost of MM to be $187,548. This highlights 
the substantial cost burden associated with MM care. Our study findings are consistent with that 
of extant literature. A study that estimated phase-specific and lifetime costs of various cancers in 
Canada reported the lifetime cost of MM to be around $120,000 (in 2009 dollars) (de Oliveira et 
al. 2016). The previous study was limited to patients from a cancer registry in Canada, and only 
included those who had been diagnosed with MM up until 2007. With the approval of several 
anti-MM drugs since 2007, and the paradigm shift seen in MM care along with increased 
survival for MM patients, our study presents a more recent estimate of costs associated with MM 
care.  
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We estimated the incremental phase-specific costs of MM for each of the four phases of 
care – pre-diagnosis, initial, continuing care, and terminal, standardized in PMPM units. The 
incremental phase-specific costs were highest for the initial care phase, followed by the terminal 
phase, with costs being slightly lower for the continuing care phase, and lowest for the pre-
diagnosis phase. Our findings are consistent with that of a previous study, conducted in Canada, 
which assessed phase-specific costs in MM, among other cancers. They reported costs to be 
highest in the initial and terminal phase, and much lower in the continuing care phase and pre-
diagnosis phase (de Oliveira et al. 2016). Our study shows that following MM diagnosis, cost 
trends followed a U-shaped curve in the sense that higher costs were seen in the initial phase, 
which then dipped in the continuing care phase, before increasing again in the terminal phase. 
This is similar to that seen in studies of other cancer types that have assessed phase-specific costs 
(Brown et al. 2002; Atkins et al. 2018). While incremental costs for the continuing phase in our 
study was lower than that for the terminal phase, it was only slightly lower than the terminal 
phase costs, and much higher than that for the pre-diagnosis phase. The continuous care phase 
cost is in contrast to that found in the previous study conducted in Canada (de Oliveira et al. 
2016). This is possibly due to the increased survival for MM patients with the approval and 
uptake of expensive, anti-MM immunotherapies in recent years (Kumar et al. 2008; Fonseca et 
al. 2017). Increasing continuing phase costs over the course of time have also been reported by 
phase-based cost assessments in other cancer types (Kaye et al. 2018). Since continuing phase 
costs primarily include costs of maintenance therapy following initial treatment and/or cancer 
relapse (R. Etzioni et al. 2002), the higher than expected continuous phase cost in our study is 
suggestive of chronic use of expensive immunotherapy drugs which are often used to prolong 
survival in patients (Kaye et al. 2018).   
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Moreover, we also identified cost drivers for each phase of MM care. For the base 
scenario (3 month terminal phase), inpatient and outpatient costs were the major drivers of costs 
in all the four phases. Pharmacy costs were a significant driver of costs in the initial and terminal 
phases, and were the biggest cost driver in the continuing care phase. Outpatient costs accounted 
for around 41%, 36%, 32%, and 35% of the incremental pre-diagnosis, initial, continuing care, 
and terminal phase MM costs respectively. Inpatient costs accounted for 57%, 38%, 19%, and 
33% of the incremental pre-diagnosis, initial, continuing care, and terminal phase MM costs 
respectively. Pharmacy costs accounted for 20%, 45%, and 25% of the incremental initial, 
continuing care, and terminal phase MM costs respectively. Trends in cost drivers seen in our 
study are consistent with that of a previous study that assessed drivers of phase-specific costs 
among commercially insured MM patients in the US (Aly et al. 2018). While though new 
treatments have prolonged survival in MM, it remains incurable. However, with the paradigm 
shift in MM treatment over the past couple of decades, MM care has been largely limited to the 
outpatient setting. This can be a possible explanation for the high outpatient cost across all 
phases. Another study, that assessed trends in costs among commercially insured MM patients, 
reported inpatient and outpatient services to be the biggest drivers of MM costs (Fonseca et al. 
2017). The high pharmacy cost, especially in the continuing care phase is possibly due to use of 
expensive, immunotherapy regimens that have been approved in the past decade or so.           
Our study has several strengths. First, we used a data-driven approach to identify duration 
of various phases of MM care. Second, since the study used SEER data, reporting of the MM 
diagnosis is likely to be more accurate as compared to studies that may have used claims-based 
algorithms to identify MM diagnosis. This is due to the fact that SEER registry data is subject to 
stringent data quality checks, in accordance with North American Association of Central Cancer 
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Registries standards, and is deemed to have 98% accuracy (Warren et al. 2002). Third, since a 
majority of NDMM patients are 65 years of age or older and Medicare is the primary payer for 
such patients, the lifetime and phase-specific cost estimates in the Medicare population help 
provide an estimate of the burden to Medicare of MM care. Moreover, the costs estimated in the 
study can be potentially used in studies evaluating the impact of interventions directed towards 
MM prevention and treatment. Furthermore, findings from our study can inform policy 
decisions, and aid evaluation of alternative payment models in MM. Information on the phase-
specific costs and cost drivers in each phase may help shape implementation of bundled payment 
models, such as Oncology Care Model, in the context of MM (Kline et al. 2017).   
The study has a few limitations. Similar to other claims analyses, coding errors can bias 
study estimates. Additionally, the study was limited to MM patients enrolled in fee-for-service 
Medicare who were 66 years of age or older at the time of their diagnosis. Hence, our findings 
are not generalizable to other populations. Moreover, the SEER registry lacked information to 
inform MM staging. Hence, our analyses could not be stratified by cancer stage. Future studies 
should estimate MM lifetime and phase-specific costs stratified by cancer stage to see if the cost 
patterns vary by cancer stage.  
Conclusion 
Our study used a data-driven approach to identify the duration of initial and terminal phases of 
care along MM care continuum. We also highlighted the substantial economic burden associated 
with MM care, in spite of the disease having low prevalence as compared to some of the other 
cancers. Findings on the economic burden of MM, its lifetime and phase-specific costs, and 
drivers of cost in each phase of MM care can aid policy discussions regarding MM care and 
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coverage. It can also be used to help design bundled payment models specific to MM (Kline et 
al. 2017).   
  
 
 
 
 
 
 84 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
  
 85 
 
Aly, Abdalla, Zoe Clancy, Brian Ung, Amit Agarwal, and Ruchit Shah. 2018. “Drivers of Phase-
Based Costs in Patients with Multiple Myeloma.” Journal of Clinical Oncology 36 (15_suppl): 
e20022–e20022. https://doi.org/10.1200/JCO.2018.36.15_suppl.e20022. 
American Cancer Society. 2018. “Key Statistics for Multiple Myeloma.” 
https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html. 
Arikian, Steven R., Dejan Milentijevic, Gary Binder, Craig J. Gibson, X. Henry Hu, Yasir 
Nagarwala, Mohamad Hussein, Frank A. Corvino, Andy Surinach, and Saad Z. Usmani. 2015. 
“Patterns of Total Cost and Economic Consequences of Progression for Patients with Newly 
Diagnosed Multiple Myeloma.” Current Medical Research and Opinion 31 (6): 1105–15. 
https://doi.org/10.1185/03007995.2015.1031732. 
Atkins, Michael, Anna D. Coutinho, Sasikiran Nunna, Komal Gupte-Singh, and Michael Eaddy. 
2018. “Confirming the Timing of Phase-Based Costing in Oncology Studies: A Case Example in 
Advanced Melanoma.” Journal of Medical Economics 21 (2): 212–17. 
https://doi.org/10.1080/13696998.2017.1391818. 
Austin, Peter C., William A. Ghali, and Jack V. Tu. 2003. “A Comparison of Several Regression 
Models for Analysing Cost of CABG Surgery.” Statistics in Medicine 22 (17): 2799–2815. 
https://doi.org/10.1002/sim.1442. 
Baker, M. S., L. G. Kessler, N. Urban, and R. C. Smucker. 1991. “Estimating the Treatment 
Costs of Breast and Lung Cancer.” Medical Care 29 (1): 40–49. 
Banegas, Matthew P., K. Robin Yabroff, Maureen C. O’Keeffe-Rosetti, Debra P. Ritzwoller, 
Paul A. Fishman, Ramzi G. Salloum, Jennifer Elston Lafata, and Mark C. Hornbrook. 2018. 
“Medical Care Costs Associated With Cancer in Integrated Delivery Systems.” Journal of the 
National Comprehensive Cancer Network 16 (4): 402–10. 
https://doi.org/10.6004/jnccn.2017.7065. 
Bang, Heejung. 2005. “Medical Cost Analysis: Application to Colorectal Cancer Data from the 
SEER Medicare Database.” Contemporary Clinical Trials 26 (5): 586–97. 
https://doi.org/10.1016/j.cct.2005.05.004. 
Barlow, William E. 2009. “Overview of Methods to Estimate the Medical Costs of Cancer.” 
Medical Care 47 (7 Suppl 1): S33–36. https://doi.org/10.1097/MLR.0b013e3181a2d847. 
Basu, A., and P. J. Rathouz. 2005. “Estimating Marginal and Incremental Effects on Health 
Outcomes Using Flexible Link and Variance Function Models.” Biostatistics 6 (1): 93–109. 
https://doi.org/10.1093/biostatistics/kxh020.
 86 
 
Basu, Anirban, Daniel Polsky, and Willard G. Manning. 2011. “Estimating Treatment Effects on 
Healthcare Costs under Exogeneity: Is There a ‘Magic Bullet’?” Health Services and Outcomes 
Research Methodology 11 (1): 1–26. https://doi.org/10.1007/s10742-011-0072-8. 
Brenner, Hermann, Adam Gondos, and Dianne Pulte. 2008. “Recent Major Improvement in 
Long-Term Survival of Younger Patients with Multiple Myeloma.” Blood 111 (5): 2521–26. 
https://doi.org/10.1182/blood-2007-08-104984. 
Brown, Martin L., Gerald F. Riley, Arnold L. Potosky, and Ruth D. Etzioni. 1999. “Obtaining 
Long-Term Disease Specific Costs of Care: Application to Medicare Enrollees Diagnosed With 
Colorectal Cancer.” Medical Care 37 (12): 1249. 
Brown, Martin L., Gerald F. Riley, Nicki Schussler, and Ruth Etzioni. 2002. “Estimating Health 
Care Costs Related to Cancer Treatment from SEER-Medicare Data.” Medical Care 40 (8): 
IV104–17. 
Chang, Stella, Stacey R. Long, Lucie Kutikova, Lee Bowman, William H. Crown, and Gary H. 
Lyman. 2006. “Burden of Pancreatic Cancer and Disease Progression: Economic Analysis in the 
US.” Oncology 70 (1): 71–80. https://doi.org/10.1159/000091312. 
Chen, Ying, David R. Lairson, Wenyaw Chan, and Xianglin L. Du. 2017. “Improved Survival in 
Medicare Patients with Multiple Myeloma: Findings from a Large Nationwide and Population-
Based Cohort.” Medical Oncology 34 (9): 153. https://doi.org/10.1007/s12032-017-1001-7. 
Christensen, Karina Garnier, Morten Fenger-Grøn, Kaare Rud Flarup, and Peter Vedsted. 2012. 
“Use of General Practice, Diagnostic Investigations and Hospital Services before and after 
Cancer Diagnosis - a Population-Based Nationwide Registry Study of 127,000 Incident Adult 
Cancer Patients.” BMC Health Services Research 12 (1): 224. https://doi.org/10.1186/1472-
6963-12-224. 
Cook, Richard. 2008. “Economic and Clinical Impact of Multiple Myeloma to Managed Care.” 
Journal of Managed Care Pharmacy 14 (7 Supp A): 19–25. 
https://doi.org/10.18553/jmcp.2008.14.S7-A.19. 
Davidoff, Amy J., Ilene H. Zuckerman, Naimish Pandya, Franklin Hendrick, Xuehua Ke, Arti 
Hurria, Stuart M. Lichtman, Arif Hussain, Jonathan P.Weiner, and Martin J. Edelman. 2013. “A 
Novel Approach to Improve Health Status Measurement in Observational Claims-Based Studies 
of Cancer Treatment and Outcomes.” Journal of Geriatric Oncology 4 (2): 157–65. 
https://doi.org/10.1016/j.jgo.2012.12.005. 
Deshmukh, Ashish A., Hui Zhao, Luisa Franzini, David R. Lairson, Elizabeth Y. Chiao, Prajnan 
Das, Michael D. Swartz, Sharon H. Giordano, and Scott B. Cantor. 2018. “Total Lifetime and 
Cancer-Related Costs for Elderly Patients Diagnosed With Anal Cancer in the United States.” 
Text. February 2018. https://doi.org/info:doi/10.1097/COC.0000000000000238. 
Deyo, Richard A., Daniel C. Cherkin, and Marcia A. Ciol. 1992. “Adapting a Clinical 
Comorbidity Index for Use with ICD-9-CM Administrative Databases.” Journal of Clinical 
Epidemiology 45 (6): 613–19. https://doi.org/10.1016/0895-4356(92)90133-8. 
 87 
 
Etzioni, Ruth D., Eric J. Feuer, Sean D. Sullivan, Danyu Lin, Chengcheng Hu, and Scott D. 
Ramsey. 1999. “On the Use of Survival Analysis Techniques to Estimate Medical Care Costs.” 
Journal of Health Economics 18 (3): 365–80. https://doi.org/10.1016/S0167-6296(98)00056-3. 
Etzioni, Ruth, Gerald F. Riley, Scott D. Ramsey, and Martin Brown. 2002. “Measuring Costs: 
Administrative Claims Data, Clinical Trials, and Beyond.” Medical Care 40 (6): III. 
Fonseca, R., S. Abouzaid, M. Bonafede, Q. Cai, K. Parikh, L. Cosler, and P. Richardson. 2017. 
“Trends in Overall Survival and Costs of Multiple Myeloma, 2000–2014.” Leukemia 31 (9): 
1915–21. https://doi.org/10.1038/leu.2016.380. 
Ghatnekar, Ola, Thor Alvegård, Nils Conradi, Stig Lenhoff, Ulf-Henrik Mellqvist, Ulf Persson, 
and Mickael Löthgren. 2008. “Direct Hospital Resource Utilization and Costs of Treating 
Patients with Multiple Myeloma in Southwest Sweden: A 5-Year Retrospective Analysis.” 
Clinical Therapeutics 30 (9): 1704–13. https://doi.org/10.1016/j.clinthera.2008.09.003. 
Gregori, Dario, Michele Petrinco, Simona Bo, Alessandro Desideri, Franco Merletti, and Eva 
Pagano. 2011. “Regression Models for Analyzing Costs and Their Determinants in Health Care: 
An Introductory Review.” International Journal for Quality in Health Care 23 (3): 331–41. 
https://doi.org/10.1093/intqhc/mzr010. 
Hornbrook, Mark C., Paul A. Fishman, Debra P. Ritzwoller, Jennifer Elston Lafata, Maureen C. 
O’Keeffe-Rosetti, and Ramzi G. Salloum. 2013. “WHEN DOES AN EPISODE OF CARE FOR 
CANCER BEGIN?” Medical Care 51 (4): 324–29. 
https://doi.org/10.1097/MLR.0b013e3182731277. 
Huang, Yijian. 2009. “Cost Analysis with Censored Data.” Medical Care 47 (7 Suppl 1): S115–
19. https://doi.org/10.1097/MLR.0b013e31819bc08a. 
International Myeloma Working Group. 2003. “Criteria for the Classification of Monoclonal 
Gammopathies, Multiple Myeloma and Related Disorders: A Report of the International 
Myeloma Working Group.” British Journal of Haematology 121 (5): 749–57. 
https://doi.org/10.1046/j.1365-2141.2003.04355.x. 
Kaye, Deborah R., Hye Sung Min, Lindsey A. Herrel, James M. Dupree, Chad Ellimoottil, and 
David C. Miller. 2018. “Costs of Cancer Care Across the Disease Continuum.” The Oncologist 
23 (7): 798–805. https://doi.org/10.1634/theoncologist.2017-0481. 
Kazandjian, Dickran. 2016. “Multiple Myeloma Epidemiology and Survival: A Unique 
Malignancy.” Seminars in Oncology, Multiple Myeloma, 43 (6): 676–81. 
https://doi.org/10.1053/j.seminoncol.2016.11.004. 
Kim, Hyune-Ju, Michael P. Fay, Eric J. Feuer, and Douglas N. Midthune. 2000. “Permutation 
Tests for Joinpoint Regression with Applications to Cancer Rates.” Statistics in Medicine 19 (3): 
335–51. https://doi.org/10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-
Z. 
 88 
 
Kline, Ron, Kerin Adelson, Jeffrey J. Kirshner, Larissa M. Strawbridge, Marsha Devita, Naralys 
Sinanis, Patrick H. Conway, and Ethan Basch. 2017. “The Oncology Care Model: Perspectives 
From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in 
Academia and the Community.” American Society of Clinical Oncology Educational Book, no. 
37 (May): 460–66. https://doi.org/10.1200/EDBK_174909. 
Koleva, D., S. Cortelazzo, C. Toldo, and L. Garattini. 2011. “Healthcare Costs of Multiple 
Myeloma: An Italian Study.” European Journal of Cancer Care 20 (3): 330–36. 
https://doi.org/10.1111/j.1365-2354.2009.01153.x. 
Krahn, Murray D., Brandon Zagorski, Audrey Laporte, Shabbir M. H. Alibhai, Karen E. 
Bremner, George Tomlinson, Padraig Warde, and Gary Naglie. 2010. “Healthcare Costs 
Associated with Prostate Cancer: Estimates from a Population-Based Study.” BJU International 
105 (3): 338–46. https://doi.org/10.1111/j.1464-410X.2009.08758.x. 
Kristinsson, Sigurdur Yngvi, Ola Landgren, Paul W. Dickman, Åsa Rangert Derolf, and Magnus 
Björkholm. 2007. “Patterns of Survival in Multiple Myeloma: A Population-Based Study of 
Patients Diagnosed in Sweden From 1973 to 2003.” Journal of Clinical Oncology 25 (15): 1993–
99. https://doi.org/10.1200/JCO.2006.09.0100. 
Kumar, Shaji K., S. Vincent Rajkumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. 
Hayman, Francis K. Buadi, Steven R. Zeldenrust, et al. 2008. “Improved Survival in Multiple 
Myeloma and the Impact of Novel Therapies.” Blood 111 (5): 2516–20. 
https://doi.org/10.1182/blood-2007-10-116129. 
Lang, Kathleen, Lisa M. Lines, David W. Lee, Jonathan R. Korn, Craig C. Earle, and Joseph 
Menzin. 2009. “Lifetime and Treatment-Phase Costs Associated With Colorectal Cancer: 
Evidence from SEER-Medicare Data.” Clinical Gastroenterology and Hepatology 7 (2): 198–
204. https://doi.org/10.1016/j.cgh.2008.08.034. 
Lipscomb, Joseph, Marek Ancukiewicz, Giovanni Parmigiani, Vic Hasselblad, Greg Samsa, and 
David B. Matchar. 1998. “Predicting the Cost of Illness: A Comparison of Alternative Models 
Applied to Stroke.” Medical Decision Making 18 (2_suppl): S39–56. 
https://doi.org/10.1177/0272989X98018002S07. 
MacEwan, Joanna P., Katharine Batt, Wes Yin, Desi Peneva, Steve Sison, Seanna Vine, and 
Clara Chen. 2018. “Economic Burden of Multiple Myeloma among Patients in Successive Lines 
of Therapy in the United States.” Leukemia & Lymphoma 59 (4): 941–49. 
https://doi.org/10.1080/10428194.2017.1361035. 
Mihaylova, Borislava, Andrew Briggs, Anthony O’Hagan, and Simon G. Thompson. n.d. 
“Review of Statistical Methods for Analysing Healthcare Resources and Costs.” Health 
Economics 20 (8): 897–916. https://doi.org/10.1002/hec.1653. 
Oliveira, Claire de, Karen E. Bremner, Reka Pataky, Nadia Gunraj, Mahbubul Haq, Kelvin 
Chan, Winson Y. Cheung, Jeffrey S. Hoch, Stuart Peacock, and Murray D. Krahn. 2013. “Trends 
 89 
 
in Use and Cost of Initial Cancer Treatment in Ontario: A Population-Based Descriptive Study.” 
CMAJ Open 1 (4): E151–58. https://doi.org/10.9778/cmajo.20130041. 
Oliveira, Claire de, Reka Pataky, Karen E. Bremner, Jagadish Rangrej, Kelvin K. W. Chan, 
Winson Y. Cheung, Jeffrey S. Hoch, Stuart Peacock, and Murray D. Krahn. 2016. “Phase-
Specific and Lifetime Costs of Cancer Care in Ontario, Canada.” BMC Cancer 16 (1): 809. 
https://doi.org/10.1186/s12885-016-2835-7. 
Palumbo, Antonio. 2012. “Multiple Myeloma.” Current Opinion in Oncology 24 (February): S1. 
https://doi.org/10.1097/01.cco.0000410242.38332.78. 
Paramore, L. Clark, Simu K. Thomas, Kevin B. Knopf, Lael S. Cragin, and Kathy H. Fraeman. 
2006. “Estimating Costs of Care for Patients with Newly Diagnosed Metastatic Colorectal 
Cancer.” Clinical Colorectal Cancer 6 (1): 52–58. https://doi.org/10.3816/CCC.2006.n.021. 
Petrucci, Maria Teresa, Elisabetta Calabrese, Anna Levi, Vincenzo Federico, Michela Ceccolini, 
Rita Rizzi, Alessandro Gozzetti, et al. 2013. “Cost of Illness in Patients with Multiple Myeloma 
in Italy: The CoMiM Study.” Tumori Journal 99 (4): e193–202. 
https://doi.org/10.1177/030089161309900434. 
Raikou, M., and A. McGuire. 2004. “Estimating Medical Care Costs under Conditions of 
Censoring.” Journal of Health Economics 23 (3): 443–70. 
https://doi.org/10.1016/j.jhealeco.2003.07.002. 
Roy, Anuja, Jonathan K. Kish, Lisa Bloudek, David S. Siegel, Sundar Jagannath, Denise Globe, 
Emil T. Kuriakose, and Kristen Migliaccio-Walle. 2015. “Estimating the Costs of Therapy in 
Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.” American 
Health & Drug Benefits 8 (4): 204–15. 
Seidler, Anne M., Michelle L. Pennie, Emir Veledar, Steven D. Culler, and Suephy C. Chen. 
2010. “Economic Burden of Melanoma in the Elderly Population: Population-Based Analysis of 
the Surveillance, Epidemiology, and End Results (SEER)–Medicare Data.” Archives of 
Dermatology 146 (3): 249–56. https://doi.org/10.1001/archdermatol.2009.389. 
Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. 2018. “Cancer Statistics, 2018.” 
CA: A Cancer Journal for Clinicians 68 (1): 7–30. https://doi.org/10.3322/caac.21442. 
Taplin, Stephen H., William Barlow, Nicole Urban, Margaret T. Mandelson, Deborah J. Timlin, 
Laura Ichikawa, and Pauline Nefcy. 1995. “Stage, Age, Comorbidity, and Direct Costs of Colon, 
Prostate, and Breast Cancer Care.” JNCI: Journal of the National Cancer Institute 87 (6): 417–
26. https://doi.org/10.1093/jnci/87.6.417. 
Teitelbaum, April, Abbie Ba-Mancini, Hui Huang, and Henry J. Henk. 2013. “Health Care Costs 
and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based 
Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims 
Data.” The Oncologist 18 (1): 37–45. https://doi.org/10.1634/theoncologist.2012-0113. 
 90 
 
Warren, Joan L., Carrie N. Klabunde, Deborah Schrag, Peter B. Bach, and Gerald F. Riley. 2002. 
“Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to 
the United States Elderly Population.” Medical Care 40 (8): IV3–18. 
Wijeysundera, Harindra C., Márcio Machado, Xuesong Wang, Gabrielle van der Velde, Nancy 
Sikich, William Witteman, Jack V. Tu, et al. 2010. “Cost-Effectiveness of Specialized 
Multidisciplinary Heart Failure Clinics in Ontario, Canada.” Value in Health 13 (8): 915–21. 
https://doi.org/10.1111/j.1524-4733.2010.00797.x. 
Wijeysundera, Harindra C, Xuesong Wang, George Tomlinson, Dennis T Ko, and Murray D 
Krahn. 2012. “Techniques for Estimating Health Care Costs with Censored Data: An Overview 
for the Health Services Researcher.” ClinicoEconomics and Outcomes Research: CEOR 4 
(June): 145–55. https://doi.org/10.2147/CEOR.S31552. 
Yabroff, K. Robin, Elizabeth B. Lamont, Angela Mariotto, Joan L. Warren, Marie Topor, Angela 
Meekins, and Martin L. Brown. 2008. “Cost of Care for Elderly Cancer Patients in the United 
States.” JNCI: Journal of the National Cancer Institute 100 (9): 630–41. 
https://doi.org/10.1093/jnci/djn103. 
Yabroff, K. Robin, Joan L. Warren, Kevin Knopf, William W. Davis, and Martin L. Brown. 
2005. “Estimating Patient Time Costs Associated with Colorectal Cancer Care.” Medical Care 
43 (7): 640–48. 
Yabroff, K. Robin, Joan L. Warren, Deborah Schrag, Angela Mariotto, Angela Meekins, Marie 
Topor, and Martin L. Brown. 2009. “Comparison of Approaches for Estimating Incidence Costs 
of Care for Colorectal Cancer Patients.” Medical Care 47 (7): S56–63. 
     
 
 
 91 
 
 
 
 
 
 
 
APPENDIX A 
  
 92 
 
Table 2.1 – Clinical and sociodemographic characteristics of elderly NDMM patients and 
matched elderly non-cancer beneficiaries enrolled in Medicare, 2006-2016 
Demographic and 
Clinical Characteristics 
Category Non-cancer 
group  
MM group p 
N = 4,533 N = 4,533 
Living in urban areas (n, 
%) 
No 313 6.9% 524 11.6% 
<0.001 
Yes 4,220 93.1% 4,009 88.4% 
Geographical region (n, 
%) 
Northeast 768 16.9% 954 21.0% 
<0.001 
South 941 20.8% 1,231 27.2% 
Midwest 424 9.3% 575 12.7% 
West 2,400 53.0% 1,773 39.1% 
Gender (n, %) Male 1,837 40.5% 2,159 47.6% 
<0.001 
Female 2,696 59.5% 2,374 52.4% 
Race (n, %) White 3,253 71.8% 3,418 75.4% 
<0.001 
African 
American 332 7.3% 663 14.6% 
Hispanic 230 5.1% 130 2.9% 
Other 718 15.8% 322 7.1% 
Charlson Comorbidity 
Index score category (n, 
%) 
0 1,567 34.6% 1,156 25.5% 
<0.001 
1 937 20.7% 964 21.3% 
2 586 12.9% 709 15.6% 
3+ 1,443 31.8% 1,704 37.6% 
Age category (n, %) 66-69 2,046 45.1% 942 20.8% 
<0.001 
70-74 793 17.5% 1,278 28.2% 
75-79 504 11.1% 983 21.7% 
80-84 424 9.4% 740 16.3% 
85+ 766 16.9% 590 13.0% 
Disability status (n, %) No 3,460 76.3% 3,668 80.9% 
<0.001 
Yes 1,073 23.7% 865 19.1% 
Death (n, %) No 2,460 54.3% 2,460 54.3% 
- 
Yes 2,073 45.7% 2,073 45.7% 
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Table 2.2 – Unadjusted comparisons between elderly NDMM and non-cancer 
Medicare beneficiaries on lifetime costs, and phase-specific costs (3 month terminal 
phase), 2007-2016 
Cost Type (PMPM) MM group (in US $) 
Non-cancer group 
(in US$) 
p 
  Mean Std. Dev Mean Std. Dev 
Disease Lifetime 212,474.7 149,539.6 54,085.6 78,265.3 <0.001 
Pre-diagnosis Phase 2,080.9 3,971.0 1,566.8 4,601.3 <0.001 
Outpatient 790.6 1,022.6 395.6 821.6 <0.001 
Inpatient 896.0 3,244.4 733.4 3,946.9 <0.001 
Part D 292.2 658.2 268.6 465.6 0.124 
Other 102.1 416.4 169.3 696.9 0.643 
Initial Phase 10,384.5 9,108.2 1,618.2 4,177.1 <0.001 
Outpatient 3,976.7 3,122.5 431.8 953.1 <0.001 
Inpatient 3,685.2 6,936.0 692.5 3,365.9 <0.001 
Part D 2,369.3 3,259.9 284.6 590.0 <0.001 
Other 353.3 726.2 209.4 831.9 <0.001 
Continuing Care 
Phase 6,082.8 5,582.0 1,495.0 3,096.5 <0.001 
Outpatient 1,997.7 2,045.7 383.2 784.7 <0.001 
Inpatient 1,270.1 3,315.8 667.4 2,305.8 <0.001 
Part D 2,566.9 3,141.5 237.1 436.2 <0.001 
Other 248.1 655.7 207.4 690.1 <0.001 
Terminal Phase 14,417.0 11,572.1 8,853.1 13,575.5 <0.001 
Outpatient 3,424.2 3,180.1 1,404.0 2,021.7 <0.001 
Inpatient 7,845.3 9,572.2 6,128.9 12,248.5 <0.001 
Part D 1,846.8 3,207.5 331.2 498.4 <0.001 
Other 1,300.8 1,606.8 989.0 1,641.4 <0.001 
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Table 2.3 - Unadjusted comparisons between elderly NDMM and non-cancer 
Medicare beneficiaries on lifetime costs, and phase-specific costs (8 month terminal 
phase), 2007-2016 
Cost Type (PMPM) MM group (in US $) 
Non-cancer group 
(in US$) 
p 
  Mean Std. Dev Mean Std. Dev 
Disease Lifetime 217,039.2 153,819.4 56,008.0 81,928.1 <0.001 
Pre-diagnosis Phase 2,080.9 3,971.0 1,566.8 4,601.3 <0.001 
Outpatient 790.6 1,022.6 395.6 821.6 <0.001 
Inpatient 896.0 3,244.4 733.4 3,946.9 <0.001 
Part D 292.2 658.2 268.6 465.6 0.124 
Other 102.1 416.4 169.3 696.9 0.643 
Initial Phase 10,023.4 8,591.0 1,443.5 4,362.3 <0.001 
Outpatient 3,962.4 3,106.7 399.6 885.0 <0.001 
Inpatient 3,306.9 6,276.3 606.8 3,616.4 <0.001 
Part D 2,434.6 3,308.0 274.7 594.4 <0.001 
Other 319.6 668.7 162.5 696.8 <0.001 
Continuing Care 
Phase 5,787.4 4,848.5 1,220.9 2,539.2 <0.001 
Outpatient 1,933.3 1,955.3 344.7 709.6 <0.001 
Inpatient 1,039.8 2,311.9 487.3 1,792.8 <0.001 
Part D 2,607.4 3,149.6 230.7 444.1 <0.001 
Other 206.9 584.7 158.1 569.4 <0.001 
Terminal Phase 11,685.1 8,243.3 5,919.0 7,431.9 <0.001 
Outpatient 3,241.3 2,739.2 1,061.7 1,529.4 <0.001 
Inpatient 5,354.1 6,263.5 3,679.0 6,397.3 <0.001 
Part D 2,205.7 3,153.8 374.4 480.3 <0.001 
Other 883.9 1,155.4 803.9 1,386.1 <0.001 
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Table 2.4 – Multivariable analysis between elderly NDMM and non-cancer Medicare beneficiaries on disease lifetime and 
phase-specific costs (3 month terminal phase), 2007-2016  
Cost Type 
(PMPM) 
MM group (mean, in US $) 
Non-cancer group (mean, in 
US$) 
Attributable to MM (mean, in 
US$) 
  Estimate 95% LCL 
95% 
UCL 
Estimate 
95% 
LCL 
95% 
UCL 
Estimate 95% LCL 
95% 
UCL 
Disease Lifetime 234,001.7 232,231.7 235,870.3 49,507.2 49,132.7 49,902.5 184,494.5 183,098.9 185,967.7 
Pre-diagnosis 
Phase 2,588.5 2,530.7 2,647.4 1,344.4 1,314.3 1,375.0 1,244.1 1,216.3 1,272.4 
Outpatient 872.8 861.6 884.9 365.2 360.5 370.2 507.6 501.1 514.7 
Inpatient 1,247.3 1,218.7 1,277.6 543.3 522.8 564.6 704.0 695.5 712.9 
Part D 291.7 288.7 294.8 270.5 267.7 273.4 21.2 20.9 21.4 
Other 182.1 174.5 189.5 152.7 146.4 158.9 29.4 28.2 30.5 
Initial Phase 12,556.7 12,411.8 12,699.7 1,375.4 1,359.6 1,391.1 11,181.3 11,052.2 11,308.6 
Outpatient 4,368.8 4,335.6 4,403.9 395.8 392.8 399.0 3,973.0 3,942.8 4,004.9 
Inpatient 4,820.9 4,735.7 4,904.7 545.9 536.7 555.0 4,275.0 4,199.0 4,349.7 
Part D 2,507.7 2,493.0 2,523.9 270.3 268.8 272.1 2,237.4 2,224.2 2,251.8 
Other 867.8 839.3 894.9 146.9 142.0 151.4 720.9 697.2 743.5 
Continuing Care 
Phase 6,967.5 6,896.9 7,041.9 1,333.5 1,320.0 1,347.7 5,634.0 5,576.9 5,694.1 
Outpatient 2,165.5 2,148.7 2,183.4 364.0 361.1 367.0 1,801.5 1,787.6 1,816.4 
Inpatient 1,644.7 1,623.4 1,667.5 558.0 549.6 566.9 1,086.8 1,073.8 1,100.6 
Part D 2,750.6 2,736.3 2,766.1 224.8 223.6 226.1 2,525.8 2,512.6 2,540.1 
Other 410.4 399.0 421.4 196.0 190.6 201.3 214.4 208.4 220.1 
Terminal Phase 15,364.4 15,285.6 15,447.1 9,084.3 9,037.7 9,133.2 6,280.1 6,247.9 6,313.9 
Outpatient 3,699.3 3,676.5 3,722.3 1,518.4 1,509.1 1,527.9 2,180.9 2,167.5 2,194.4 
Inpatient 8,411.2 8,353.0 8,472.1 6,350.9 6,306.9 6,396.9 2,060.3 2,046.1 2,075.2 
Part D 1,946.5 1,937.5 1,955.7 346.2 344.6 347.8 1,600.3 1,592.9 1,607.9 
Other 1,266.9 1,257.2 1,276.0 806.2 800.0 811.9 460.7 457.3 464.1 
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Table 2.5 - Multivariable analysis between elderly NDMM and non-cancer Medicare beneficiaries on disease lifetime and 
phase-specific costs (8 month terminal phase), 2007-2016  
Cost Type (PMPM) MM group (mean, in US $) 
Non-cancer group (mean, in 
US$) 
Attributable to MM (mean, in 
US$) 
  Estimate 95% LCL 
95% 
UCL 
Estimate 
95% 
LCL 
95% 
UCL 
Estimate 95% LCL 
95% 
UCL 
Disease Lifetime 238,860.4 237,049.2 240,767.4 51,312.7 50,923.6 51,722.3 187,547.7 186,125.6 189,045.0 
Pre-diagnosis 
Phase 2,588.5 2,530.7 2,647.4 1,344.4 1,314.3 1,375.0 1,244.1 1,216.3 1,272.4 
Outpatient 872.8 861.6 884.9 365.2 360.5 370.2 507.6 501.1 514.7 
Inpatient 1,247.3 1,218.7 1,277.6 543.3 522.8 564.6 704.0 695.5 712.9 
Part D 291.7 288.7 294.8 270.5 267.7 273.4 21.2 20.9 21.4 
Other 182.1 174.5 189.5 152.7 146.4 158.9 29.4 28.2 30.5 
Initial Phase 12,179.4 12,045.4 12,314.1 1,282.5 1,268.4 1,296.7 10,896.9 10,777.0 11,017.4 
Outpatient 4,354.4 4,322.5 4,388.5 375.6 372.9 378.6 3,978.8 3,949.6 4,009.9 
Inpatient 4,378.2 4,300.5 4,453.7 503.5 495.1 511.6 3,874.7 3,805.3 3,942.1 
Part D 2,584.1 2,568.3 2,601.0 264.0 262.4 265.7 2,320.1 2,305.9 2,335.3 
Other 875.2 846.2 903.3 121.9 117.8 125.8 753.3 728.3 777.4 
Continuing Care 
Phase 6,597.5 6,527.3 6,668.8 1,091.5 1,079.9 1,103.3 5,506.0 5,447.4 5,565.5 
Outpatient 2,106.1 2,090.0 2,122.9 332.6 330.0 335.2 1,773.5 1,760.0 1,787.7 
Inpatient 1,321.9 1,302.2 1,342.5 351.7 344.9 358.7 970.2 957.3 983.8 
Part D 2,830.2 2,814.4 2,846.7 218.7 217.5 220.0 2,611.5 2,596.9 2,626.8 
Other 351.7 342.5 360.8 156.0 151.9 160.0 195.7 190.6 200.8 
Terminal Phase 12,362.5 12,304.2 12,422.4 5,927.8 5,899.8 5,956.5 6,434.8 6,404.4 6,465.9 
Outpatient 3,481.7 3,460.7 3,503.4 1,108.1 1,101.5 1,115.0 2,373.6 2,359.2 2,388.3 
Inpatient 5,720.6 5,682.9 5,759.0 3,792.6 3,768.2 3,817.4 1,928.0 1,914.6 1,941.6 
Part D 2,315.2 2,305.1 2,325.9 393.2 391.4 395.0 1,922.0 1,913.7 1,930.9 
Other 852.9 844.8 860.3 617.0 611.2 622.4 235.9 233.6 237.9 
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Table 2.6 Joinpoint regression estimates for identifying duration of initial and terminal 
phases of care among elderly NDMM patients who died during 2007-2016 
 
Outcome Joinpoint Estimate 95% 
LCL 
95% 
UCL 
MPC (95% 
CI) 
p 
Initial Phase 1 4 3 6 
15.0 (12.2-
17.7) <0.001 
  2 14 10 19 2.7 (2.0-3.4) <0.001 
Terminal Phase 1 3 3 5 
20.8 (17.3-
24.1) <0.001 
  2 8 7 11 6.9 (5.4-8.4) <0.001 
  3 34 26 45 1.2 (1.1-1.4) <0.001 
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Figure 2.1 – Joinpoint regression for initial phase 
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Figure 2.2 – Joinpoint regression for terminal phase 
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CHAPTER 4: PAPER 3 
End-of-Life Care in Multiple Myeloma – Trends, and Impact of Palliative Care 
 
Introduction 
Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal growth of 
clonal plasma cells. More than 10,000 people die from MM each year in the United States (US), 
with an estimated 12,770 deaths reported in 2018 (Siegel, Miller, and Jemal 2018). Even though 
MM treatment has advanced significantly in the past two decades, MM still remains incurable. 
With deaths from MM rising every year, an increasing number of MM patients find themselves 
at the end of their life each year. As per the National Quality Forum (NQF), end-of-life (EOL) 
care is defined as “comprehensive care for life-limiting illnesses that meets the patient’s medical, 
physical, psychological, spiritual, and social needs” (National Quality Forum 2012).  
EOL costs impose a significant burden on payers, patients, and society. It is very 
important to appropriately manage EOL care in order to ensure that patients receive medical care 
that is of high quality and cost-effective at the same time. A Medicare analysis revealed that even 
though around 5% of the beneficiaries die each year, they account for around 30% of total 
Medicare expenditures, and around 33% of costs incurred in the last year of life are attributable 
to the last month before death (Emanuel et al. 2002). Empirical evidence suggests that cancer 
patients often receive cost-intensive aggressive medical care before death, even when it may be
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 of little clinical value and can negatively affect their quality of life (Bekelman et al. 2016; 
Tangka et al. 2015; Langton et al. 2016; Zhang et al. 2009; Garrido et al. 2015); and cancer 
patients who die from cancer incur greater healthcare expenditures at EOL as compared to non-
cancer patients or cancer patients who die from other reasons (Tangka et al. 2015; Langton et al. 
2016).  However, aggressive medical care before death is neither beneficial from a clinical 
perspective nor from a humanistic point of view. A study conducted across several cancer care 
centers across the US revealed that higher treatment costs in the last week of death was 
associated with poorer quality of life among patients with advanced cancer (Zhang et al. 2009). 
Incorporating palliative care into clinical disease management of cancer patients nearing their 
EOL is an effective technique for providing high quality, cost-effective care and has been shown 
to improve EOL cancer care outcomes, such as overall survival and quality of life, and early 
palliative care has been associated with use of less aggressive medical care at EOL (Perone, 
Riall, and Olino 2016; Temel et al. 2010; Howie and Peppercorn 2013; Schenker and Arnold 
2017; Ferrell et al. 2017). 
  However, it has been reported that patients with hematological malignancies, including 
MM, receive aggressive cancer-related care near death and have lower use of palliative care and 
hospice services as compared to patients with solid tumors (Earle et al. 2008; Ho et al. 2011; Hui 
et al. 2012; Sexauer et al. 2014; Tang et al. 2009; Cheng et al. 2005). For example, one study 
reported that the proportion of patients receiving palliative care was only 18% for hematologic 
malignancies as compared to 44% for solid tumors (Hui et al. 2012). A retrospective cohort 
study that compared patients with hematologic and solid cancers on a NQF and American 
Society of Clinical Oncology (ASCO) endorsed measure of quality of EOL care for 
aggressiveness of care found that patients with hematologic cancers have significantly higher 
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rates for all aggressiveness of care indicators than patients with solid cancers. It also reported 
hematologic cancer patients to have higher targeted therapy use and lower use of palliative care 
services as compared to solid cancer patients (Hui et al. 2014). The difference in quality of EOL 
care between hematologic cancers and solid cancers can be attributed to a variety of reasons. One 
of the major barriers towards inception of EOL care among patients with hematologic cancers is 
lack of clarity on onset of EOL. This problem is compounded by the availability of treatments in 
advanced stages and the rapid  decline of patient’s health near death (Fadul et al. 2008). Other 
factors that have been reported as barriers to quality of EOL care among patients with 
hematologic cancers include unrealistic patient expectations and difficulties in conducting EOL 
discussions with patients (Odejide et al. 2014).  
The treatment landscape in MM has seen a drastic change for the past two decades with 
the advent of stem cell transplant and novel agents. While patients with MM are living longer, 
the burden of the disease and side effects of the treatments often lead to high symptom burden. 
Studies have reported high prevalence of pain, fatigue and drowsiness among MM patients 
(Snowden et al. 2011; Porta-Sales et al. 2015; Niscola et al. 2007). This underlines the need for 
holistic assessment of MM patients and compliment cancer-directed treatment with palliative 
care, as evidenced by supportive care guidelines in MM (Snowden et al. 2011). A retrospective 
study that assessed the effectiveness of early palliative care among MM patients demonstrated 
significant improvements in pain control, in addition to reduction in physical and emotional 
symptom burden (Porta-Sales et al. 2017).    
While a few studies have assessed trends in EOL care in hematologic malignancies in 
general, no study has yet assessed trends in EOL care among MM patients. Similarly, there is 
very limited evidence on the impact of palliative care services on quality of care, healthcare 
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utilization, and costs at EOL. Given the changing landscape of MM treatment and the significant 
symptom burden associated with the disease, assessing trends in quality of EOL care among MM 
patients will significantly contribute to the body of literature in MM, and help policy makers and 
medical decision makers aim tailored intervention programs to improve quality of EOL care. 
Moreover, an assessment of impact of palliative care consultation on quality of EOL care, 
healthcare utilization and costs will add to the evidence base on palliative care in MM, and could 
be used by clinicians and policy makers to better integrate palliative with routine MM care. In 
the current study, we aimed to assess trends in EOL care, and the impact of palliative care 
consultations on quality of care, healthcare utilization and costs at EOL among elderly newly 
diagnosed MM patients.   
Methods 
Data Source and Study Design 
A retrospective analysis was conducted using National Cancer Institute’s (NCI) SEER database 
linked with Medicare administrative claims database. The NCI’s SEER program is an 
epidemiologic surveillance system that contains data collected from population-based tumor 
registries and was designed to track cancer incidence and mortality in the US. It includes clinical 
and demographic information in addition to information on cause of death for people with 
cancer, and is collected from 18 participating cancer registries across the US. Medicare is a 
federally administered health insurance program which covers elderly Americans who are 65 
years of age or older, as well as younger patients with disabilities and end-stage renal disease 
(ESRD). The Medicare administrative claims database provides information on claims for 
covered healthcare services for beneficiaries enrolled in Medicare. The SEER-linked Medicare 
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claims database provides patient-level data for Medicare beneficiaries with cancer (Warren et al. 
2002). 
 The current study utilized 2007-2015 SEER data linked with 2006-2016 Medicare claims 
data. The SEER data consists of the Patient Entitlement and Diagnosis Summary File (PEDSF) 
that includes clinical, demographic, and Medicare enrollment information for individuals with 
cancer. The Medicare claims data consists of the Medicare Provider Analysis and Review 
(MEDPAR), National Claims History (NCH), Outpatient (OUTPT), Home Health Agency 
(HHA), Hospice, Durable Medical Equipment (DME), and Prescription Drug Event (PDE) files. 
The MEDPAR file contains all Medicare Part A claims indication short stay, long stay, skilled 
nursing facility (SNF) stays as well as International Classification of Diseases, ninth revision 
(ICD-9) or International Classification of Diseases, tenth revision (ICD-10) diagnoses and 
procedures performed during each stay. The NCH file contains all Medicare Part B claims 
generated due to physician or supplier services in clinics and hospitals, whereas the OUTPT file 
contains all Medicare Part B claims outpatient providers. Both NCH and OUTPT files were used 
to obtain information such as procedural Healthcare Common Procedure Coding System 
(HCPCS) codes, diagnoses, date of claims, treatment administration, and reimbursement 
amounts. The HHA file contains claims for all home health care services such as number and 
types of visits and diagnoses. The hospice file contains claims submitted by hospice providers, 
and has details on type of care (inpatient care, routine home care) as well as terminal diagnosis 
associated with that care. The DME file contains claims with information on use of oral and 
intravenous chemotherapy, and infusion pumps used. The PDE file contains information about 
drug utilization such as, date of prescription fill, drug dispensed, quantity dispensed, days 
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supplied, total cost, and out-of-pocket cost. The Institutional Review Board (IRB) at the 
University of Mississippi has approved the study.  
Study sample 
This study included Medicare beneficiaries who entered the SEER registry from 2007 through 
2015, and were diagnosed with MM as their primary cancer. All beneficiaries with primary MM 
will be identified based on the International Classification of Diseases for Oncology, 3rd Edition 
(ICD-O-3) code of MM (9732). The last month of a MM patient’s life was considered as the 
EOL period. MM patients needed to be 66 years of age or older at the time of death, died during 
the study period (2007-2016), and have continuous enrollment in Medicare Parts A, B and D in 
the 12 months prior to the EOL period to be included in the study. MM patients were excluded 
from the study sample if they had an unknown diagnosis month or year, had a missing date of 
death, or if MM diagnosis was made at the time of death or within 30 days of date of death.  
Moreover, MM patients were excluded from the study sample if they ever had a diagnosis for 
any other type of cancer, or if they were enrolled in a health maintenance organization (HMO) in 
the 12-month period prior to the EOL period.  
All MM patients included in the study sample were assigned to the palliative care 
consultation (PCC) cohort or non-PCC cohort based on whether they had a consultation for 
palliative care in the 12-month period prior to death. PCC visits were identified using the ICD-9 
and ICD-10 codes of V66.7 and Z51.5 respectively. For MM patients with multiple PCC visits, 
the first such visit was considered and, was referred to as index PCC.   
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Outcome Measures 
The key outcomes of interest were EOL care outcomes, healthcare resource utilization, and 
healthcare costs during EOL. EOL care outcomes included the following 6 NQF/ASCO 
indicators (Hui et al. 2014; Earle et al. 2003) in the EOL period:  > 1 emergency department 
visit, > 1 hospital admission, > 14 days of hospitalization, an intensive care unit (ICU) 
admission, death in a hospital, and use of chemotherapy in the last 14 days of life. Additionally, 
we assessed a composite aggressiveness of EOL care measure, which was determined based on 
the presence of at least one of the 6 NQF/ASCO indicators. Consistent with previous research, 
ICU admission will be defined as presence of one or more of the following in the EOL period: 
ICU indicator code, intensive care day count of 1 or more, and procedure codes for continuous 
invasive mechanical ventilation, or cardiopulmonary resuscitation, or insertion of feeding tubes 
(Accordino et al. 2016; Quan, Parsons, and Ghali 2004; Cooke et al. 2014; Morden et al. 2012).  
Furthermore, we assessed all-cause healthcare resource utilization and healthcare costs at 
the EOL. Resource utilization included number of ICU admissions and ER visits. We considered 
payments made by Medicare when calculating healthcare costs. All cost estimates were adjusted 
to 2016 US dollars.  
Covariates 
Study covariates included patient demographic and clinical characteristics at baseline (i.e., prior 
to beginning of the EOL period). Baseline demographic covariates included age, sex, race, urban 
residency, geographical region, and marital status. Baseline clinical covariates included 
comorbidity, and disability status. Comorbidity was assessed using the Deyo adaption of the 
Charlson Comorbidity Index (CCI) (Deyo, Cherkin, and Ciol 1992). Disability status was 
 108 
 
defined as a binary variable based on a claim-based algorithm during the 12-month baseline 
period prior to beginning of the EOL period (Davidoff et al. 2010; Griffiths et al. 2011; Williams 
et al. 2015). It was based on claims for one or more of the following – hospice care, home health 
agency, skilled nursing facility, oxygen use, wheelchair use, and walking aid, and was combined 
into a score of 0 (none) or 1 (use of any service). Moreover, months of survival post MM 
diagnosis was included as a covariate in the study. 
Data Analysis 
Propensity score matching was employed to account for covariate imbalance at baseline between 
the PCC and no PCC cohorts. A 1:1 match without replacement was performed based on the 
patients’ propensity to have a PCC visit. Logistic regression was employed to obtain the 
propensity scores, and was modeled on age, urban residency, geographical region, gender, race, 
marital status, disability status, and CCI score. Mean standardized differences were used to 
assess covariate imbalance between the two cohorts post propensity score matching. A 
standardized difference less than 0.1 indicates negligible differences between the cohorts (Austin 
2011). 
Descriptive statistics were used to depict baseline patient characteristics, aggressiveness 
of EOL care outcomes, healthcare resource utilization and costs at EOL. For categorical 
variables, frequency and percentage distributions were reported. Statistical comparisons were 
conducted between cohorts using McNemar’s test or Cochrane-Mantel-Haenszel test, to account 
for the matched data. For continuous variables, mean, standard deviation (SD), median, and 
range were reported. Statistical comparisons for continuous variables were conducted using 
paired t-tests. For unadjusted healthcare costs at EOL, Wilcoxon signed rank test were used to 
test for significance between the cohorts.   
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The Cochran-Armitage trend test were employed to evaluate the change in proportion of 
elderly MM patients over time (2007 – 2016) for the following outcomes - 6 ASCO/NQF quality 
of EOL care indicators, and composite aggressiveness of EOL care outcome. Results from the 
trend test were confirmed with Joinpoint regression analysis (Kim et al. 2000) for each of the 
ASCO/NQF quality of EOL care indicators and the composite aggressiveness of EOL care 
outcome. Separate conditional logistic regression models were used to compare the ASCO/NQF 
EOL quality of care indicators and the composite aggressiveness of EOL care outcome between 
the PCC and no PCC cohorts, accounting for matching between the cohorts. All of the models 
were run controlling for months of survival post MM diagnosis and any other covariate that had 
a non-negligible mean standardized difference (greater than 0.1). 
Generalized linear models with log link and poisson distribution was employed to 
compare all-cause healthcare resource utilization at EOL between the PCC and no PCC cohorts, 
controlling for months of survival post MM diagnosis and any covariate with a non-negligible 
standardized mean difference. Generalized linear models with log link and gamma distribution 
was employed to compare all-cause healthcare cost at EOL between the PCC and no PCC 
cohorts, controlling for months of survival post MM diagnosis and any covariate with a non-
negligible standardized mean difference. For all the cost and count models, recycled prediction 
technique was used to assess the incremental impact of PCC on healthcare use and costs, to 
account for covariate imbalance (A. Basu and Rathouz 2005; Anirban Basu, Polsky, and 
Manning 2011). For this technique, the outcome was first predicted assuming every recipient to 
be in the no PCC group, and then the outcome was again predicted assuming every recipient to 
be in the PCC group. The incremental impact was then assessed by calculating the difference 
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between the predicted outcomes for the PCC and no PCC groups. Percentile bootstrapping with 
1000 replications was conducted to compute the 95% Confidence Interval (CI) for each outcome.  
Separate subgroup analyses were conducted for all multivariable analyses – one for MM 
patients that had their first PCC visit prior to EOL period (early PCC) compared to those without 
any PCC visits, and another for MM patients that had their first PCC visit in the EOL period (late 
PCC) versus those who did not have any PCC visits. All data management and analysis were 
done using National Cancer Institute’s Joinpoint regression software, SAS version 9.4, and 
STATA 15.  
Results   
5,151 elderly MM patients who died during the study period met the study inclusion and 
exclusion criteria. The sample characteristics are presented in Table 3.1. Most of the elderly MM 
patients in the sample lived in urban areas (89.1%), were white (73.7%), had a CCI score of 3 or 
more (72.4%), had disability (70.7%), and did not have any PCC visits (68.8%). Additionally, 
majority of the MM patients in the sample were female (51.2%), 75 years old or older (66.8%), 
and resided in the western or southern (67.2%) region of the US. Moreover, majority of the MM 
patients in the sample were either married (47.4%) or widowed (27.2%) at the time of MM 
diagnosis.  
Tables 3.2.1-3.2.4 depicts results of the univariate trend analysis for proportion of elderly 
MM patients that had greater than one ED visit, greater than 14 days of inpatient stay, greater 
than one inpatient admission, and ICU stay in the EOL period respectively, from 2007 to 2016. 
Additionally, results of the univariate trend analysis for proportion of elderly MM patients that 
had death in hospital, chemotherapy use in the last 14 days of life, and any aggressive EOL care 
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in the EOL period from 2007 to 2016 are presented in Table 3.2.5, Table 3.2.6, and Table 3.2.7, 
respectively. As per results of the Cochrane-Armitage trend test, there was statistically 
significant increase in the proportion of elderly MM patients with greater than one ED visits in 
the EOL period (p = 0.017), and ICU stay in the EOL period (p = 0.005), between 2007 and 
2016. Moreover, statistically significant decrease was seen in the proportion of elderly MM 
patients with greater than 14 days of inpatient stay in the EOL period (p = 0.004), and death in 
hospital (p<0.001) between 2007 and 2016. No statistically significant change was observed in 
the proportion of elderly MM patients with greater than one inpatient admission in the EOL 
period (p=0.113), chemotherapy use in the last 14 days of life (p=0.060), and any aggressive 
EOL care (p=0.703) between 2007 and 2016.  
Trend analysis results obtained from the Cochrane-Armitage trend tests were confirmed 
using Joinpoint regression analysis. Table 3.2.8 presents trend test results from the Joinpoint 
regression analysis, and Figures 3.1-3.6 depict the trends in proportion of elderly MM patients 
with greater than one ED visit, greater than 14 days of inpatient stay, greater than one inpatient 
admission, ICU stay, death in hospital, and any aggressive EOL care in the EOL period between 
2007 and 2016 respectively. As we can see, the linear trends reported in the Cochrane-Armitage 
trend tests were confirmed by the Joinpoint regression analysis. We could not conduct a 
Joinpoint regression analysis to confirm the results of the Cochrane-Armitage trend test for the 
proportion of elderly MM patients that had chemotherapy use in the last 14 days of life over 
time, since there were no patients with chemotherapy use in the last 14 days of life in certain 
years.   
For assessing the impact of PCC on aggressiveness of EOL care outcomes, healthcare 
resource utilization at EOL, and costs at EOL, 1,588 elderly MM patients with any PCC prior to 
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death were matched on age, urban residency, geographical region, gender, race, marital status, 
disability status, and CCI score to 1,588 elderly MM patients without any PCC. Table 3.3.1 
presents the descriptive characteristics for the any PCC and no PCC cohorts. As seen in Table 
3.3.1, the standardized mean difference was negligible between the two cohorts for all covariates 
included in the propensity score (P-S) matched model. The two cohorts were significantly 
different on months of survival post MM diagnosis [27 months (median) of survival post MM 
diagnosis in the any PCC group vs 18 months (median) of survival post MM diagnosis in the no 
PCC group; p <0.001].   
For the subgroup analysis between the late PCC and no PCC cohorts, 1,074 elderly MM 
patients with late PCC (first PCC visit in the EOL period) were matched to 1,074 elderly MM 
patients without any PCC. Table 3.3.2 presents the descriptive characteristics for the late PCC 
and no PCC cohorts. As seen in Table 3.3.2, the standardized mean difference was negligible 
between the two cohorts for all covariates included in the P-S matched model. The two cohorts 
were significantly different on months of survival post MM diagnosis [27 months (median) of 
survival post MM diagnosis in the late PCC group vs 18 months (median) of survival post MM 
diagnosis in the no PCC group; p <0.001]. Additionally, the two cohorts were significantly 
different on disability at baseline (64% in the late PCC group vs 67% in the no PCC group, p = 
0.046). 
For the subgroup analysis between the early PCC and no PCC cohorts, 514 elderly MM 
patients with early PCC (first PCC visit prior to beginning of the EOL period) were matched to 
514 elderly MM patients without any PCC. Table 3.3.3 presents the descriptive characteristics 
for the early PCC and no PCC cohorts. As seen in Table 3.3.3, the standardized mean difference 
was negligible between the two cohorts for all the covariates included in the P-S matched model, 
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except for disability at baseline (standardized mean difference = 0.113). The two cohorts were 
significantly different on months of survival post MM diagnosis [26 months (median) of survival 
post MM diagnosis in the early PCC group vs 18 months (median) of survival post MM 
diagnosis in the no PCC group; p = 0.001]. Additionally, the two cohorts were significantly 
different on disability at baseline (88% in the early PCC group vs 84% in the no PCC group, p = 
0.003).  
Results of the unadjusted analysis between the any PCC and no PCC cohorts on 
aggressiveness of EOL care outcomes, healthcare resource utilization at EOL, and costs at EOL 
is presented in Table 3.4.1. As compared to the no PCC group, the any PCC group had 
significantly greater proportion of patients with greater than 1 ED visits (p<0.001), greater than 
14 days of inpatient stay (p = 0.005), greater than 1 inpatient admission (p<0.001), ICU stay 
(p<0.001), death in hospital (p<0.001), and any aggressive EOL care (p<0.001). Moreover, as 
compared to the no PCC group, the any PCC group had higher healthcare resource utilization at 
EOL (p<0.001), and higher cost at EOL (p<0.001). 
Results of the unadjusted analysis between the late PCC and no PCC cohorts on 
aggressiveness of EOL care outcomes, healthcare resource utilization at EOL, and costs at EOL 
is presented in Table 3.4.2. As compared to the no PCC group, the late PCC group had 
significantly greater proportion of patients with greater than 1 ED visits (p<0.001), greater than 
14 days of inpatient stay (p<0.001), greater than 1 inpatient admission (p<0.001), ICU stay 
(p<0.001), death in hospital (p<0.001), and any aggressive EOL care (p<0.001). Moreover, as 
compared to the no PCC group, the any PCC group had higher healthcare resource utilization at 
EOL (p<0.001), and higher cost at EOL (p<0.001). 
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Results of the unadjusted analysis between the early PCC and no PCC cohorts on 
aggressiveness of EOL care outcomes, healthcare resource utilization at EOL, and costs at EOL 
is presented in Table 3.4.3. As compared to the no PCC group, the early PCC group had 
significantly lower proportion of patients with greater than 1 ED visits (p=0.022), greater than 14 
days of inpatient stay (p=0.002), greater than 1 inpatient admission (p=0.001), ICU stay 
(p<0.001), death in hospital (p<0.001), and any aggressive EOL care (p<0.001). Moreover, as 
compared to the no PCC group, the any PCC group had lower healthcare resource utilization at 
EOL (p<0.001), and lower cost at EOL (p<0.001).   
Table 3.5 depicts results of the conditional logistic regression analysis between the any 
PCC and no PCC groups on aggressiveness of EOL care outcomes (>1 ED visit, inpatient LOS > 
14 days, >1 inpatient admission, ICU stay, death in hospital, any aggressive EOL care), 
controlling for months of survival post MM diagnosis. As compared to the no PCC group, MM 
patients in the any PCC group had greater odds for all the aggressiveness of EOL care outcome 
[>1 ED visits: Odds Ratio (OR):1.4, 95% Confidence Interval (CI): 1.2-1.7; inpatient LOS >14 
days: OR: 1.3, 95% CI: 1.1-1.5; >1 inpatient admissions: OR: 1.5, 95% CI: 1.3-1.8; ICU stay: 
OR: 1.7, 95% CI: 1.5-2.0; and death in hospital: OR: 1.5, 95% CI:1.3-1.8], and the composite 
outcome of any aggressive care in EOL [OR: 1.9, 95% CI: 1.6-2.2]. Subgroup analyses showed 
that, after controlling for months of survival post MM diagnosis and disability at baseline, MM 
patients in the late PCC group had greater odds for all aggressiveness of EOL care outcomes [>1 
ED visits: OR:1.9, 95% CI: 1.5-2.3; inpatient LOS >14 days: OR: 1.7, 95% CI: 1.4-2.1; >1 
inpatient admissions: OR: 2.0, 95% CI: 1.7-2.5; ICU stay: OR: 2.8, 95% CI: 2.2-3.3; and death in 
hospital: OR: 2.2, 95% CI:1.8-2.7], and the composite outcome of any aggressive EOL care [OR: 
4.2, 95% CI: 3.3-5.3] than their matched no PCC group counterparts. However, MM patients in 
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the early PCC group had lower odds for all aggressiveness of EOL care outcomes [>1 ED visits: 
OR:0.7, 95% CI: 0.5-0.9; inpatient LOS >14 days: OR: 0.6, 95% CI: 0.4-0.8; >1 inpatient 
admissions: OR: 0.6, 95% CI: 0.4-0.8; ICU stay: OR: 0.5, 95% CI: 0.4-0.7; and death in hospital: 
OR: 0.6, 95% CI:0.4-0.8], and the composite aggressive EOL care outcome [OR: 0.5, 95% CI: 
0.4-0.6] than those in no PCC group. Conditional logistic regression models could not be run for 
the chemotherapy use in the last 14 days of life outcome, due to low event rate and model 
convergence issues.  
Results of the multivariable analysis for assessing incremental healthcare resource use at 
EOL and costs at EOL are presented in Table 3.6. After controlling for months of survival post 
MM diagnosis, the any PCC group had significantly greater healthcare resource utilization at 
EOL (incremental difference: 0.33, 95% CI: 0.33, 0.34) and costs at EOL (incremental 
difference: $5,315, 95% CI: $5,309, $5,323) as compared to the no PCC group. Subgroup 
analyses showed that, after controlling for months of survival post MM diagnosis and disability, 
the late PCC group had significantly greater healthcare resource utilization at EOL (incremental 
difference: 0.66, 95% CI: 0.65, 0.67) and costs at EOL (incremental difference: $10,272, 95% 
CI: $10,230, $10,311) than the no PCC group. However, controlling for months of survival post 
MM diagnosis and disability, the early PCC group had significantly lower healthcare resource 
utilization at EOL (incremental difference: 0.35, 95% CI: 0.34, 0.35) and costs at EOL 
(incremental difference: $4,846, 95% CI: $4,818, $4,872) than the no PCC group.  
Discussion 
MM treatment has seen a paradigm shift in the past few decades, and the availability of several 
immunotherapies has prolonged survival among patients with MM (Cowan et al. 2018; Lehners 
et al. 2018; Donk and Lokhorst 2013). This is the first study to assess trends in EOL care using a 
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population-based cohort of elderly MM patients. Results from this study will help understand the 
general trend of EOL care among elderly MM patients, and inform intervention programs 
designed to improve quality of EOL care. Additionally, this is also the first study to assess the 
impact of palliative care consultations on the aggressiveness of EOL care, healthcare resource 
utilization and healthcare costs at EOL. This information could help clinicians and policy makers 
in developing policies and interventions aimed towards improving integration of early palliative 
care with routine MM care.  
 Our findings about the trends in aggressive EOL care, among elderly MM patients, from 
2007 to 2016 are consistent with previous studies that have assessed trends in the aggressiveness 
of EOL care in other cancer types. A SEER-Medicare analysis of elderly uterine cancer patients 
reported that there was no significant difference in trend of any aggressive EOL care, inpatient 
admission in the EOL period, and chemotherapy use over time (Margolis et al. 2017). Another 
study that examined trends in aggressiveness of EOL among Medicare beneficiaries with cancer 
found that there was a significant increase in the proportion of beneficiaries with more than one 
ED visit at EOL and at least one ICU stay over time (Wang et al. 2016). Similar to our findings, 
it also reported a decrease in proportion of beneficiaries that died in hospital over time, and did 
not find any significant difference in trends of chemotherapy in the EOL period over time (Wang 
et al. 2016). A Canadian analysis of trends in aggressiveness of EOL care among cancer patients 
also reported similar results, with there being a decline in proportion of patients with multiple 
inpatient admission at EOL over time, and an increasing trend for proportion of patients with 
multiple ED visits at EOL, and EOL ICU admissions (Ho et al. 2011).  
 Additionally, we found that compared to MM patients who had no PCC visits, having 
PCC at any time prior to death is associated with greater odds of receiving aggressive EOL care 
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(41% to 86% greater odds), higher healthcare resource utilization at EOL, and higher costs at 
EOL. While these results may seem to contradict with our expectations, it is not surprising 
considering the fact that almost 70% of the patients in our sample that had a PCC visit had late 
PCC (i.e., in the last 30 days prior to death). Our subgroup analysis found that those who had a 
late PCC visit had even greater odds of receiving aggressive EOL care (89% to 317% greater 
odds) than those who did not have a PCC visit. Furthermore, MM patients who had a late PCC 
visit had much higher healthcare resource use and costs at EOL (the incremental difference being 
twice as high as that for the any PCC vs no PCC comparison) as compared to those who did not 
have a PCC visit. This is potentially because patients who had a late PCC visit were sicker than 
those that did not have a PCC visit and are more likely to be cared for in the  ED and ICU 
(Bhulani et al. 2018) where  PCC may have been preferentially made to these patients who were 
sicker and had higher symptom burden. Previous studies have found that patients with 
hematologic malignancies are usually referred for PCC later than those with solid tumors 
(Boyce, McHugh, and Lyon 2003; Delgado‐Guay et al. 2009; Zimmermann et al. 2013), and 
symptom relief is usually the major reason for PCC referrals in patients with hematologic 
cancers (Corbett et al. 2013; Auret, Bulsara, and Joske 2003; Albrecht and Rosenzweig 2012). 
Our findings are similar to that of a previous study that assessed the impact of PCC on healthcare 
resource use and costs among elderly pancreatic cancer patients in the US, and reported that 
having a PCC was not associated with reduced healthcare resource use and costs at EOL 
(Bhulani et al. 2018).  
 However, we found from our subgroup analysis between those who had early PCC visits 
(i.e, first PCC visit prior to beginning of the EOL period) and no PCC visits that having an early 
PCC visit was associated with significantly lower odds for all aggressiveness of EOL care 
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outcomes than those who did not have a PCC visit. Moreover, those who had an early PCC visit 
had significantly lower healthcare resource use and costs at EOL as compared to those who did 
not have a PCC visit. These results highlight the benefits of early palliative care consultation 
among elderly MM patients, and its potential to help avoid unnecessary treatment and 
inappropriate care at EOL. Our findings are consistent with that of previous studies. Controlled, 
prospective studies have reported reduced healthcare resource utilization and costs for patients 
that have undergone early palliative care (Brumley et al. 2007; Siderow, Silvers, and Meier 
2016). Another study, among women with gynecologic cancers, reported early palliative care to 
be associated with a reduction in aggressive EOL care and costs (Nevadunsky et al. 2014). 
Additionally, other studies have found early palliative care to be associated with lower likelihood 
of dying in hospital (Poulose, Do, and Neo 2013) and aggressive treatment in the EOL period 
(Jang et al. 2015). An early palliative care intervention program for MM patients, conducted in 
Spain, found it to improve patient’s general activity, sleep, mood, in addition to reductions in 
their symptom burden (Porta-Sales et al. 2017).  
 Our study has several strengths. First, we used a population-based cohort of elderly MM 
patients to assess trends in receiving aggressive EOL care over time. Several studies have 
reported cancer patients to receive high cost, aggressive care in the period prior to death, even 
though current evidence suggests that such care does not provide much clinical value and often 
affects their quality of life negatively (Bekelman et al. 2016; Tangka et al. 2015; Langton et al. 
2016; Zhang et al. 2009; Garrido et al. 2015). These real-world results can help inform 
interventions targeted towards reducing aggressive EOL care among MM patients. Additionally, 
this is the first study to assess the impact of PCC on aggressive EOL care outcomes, and 
healthcare resource use and costs at EOL. Results from this study can help policy makers design 
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interventions targeted towards incorporating early palliative care among MM patients, in order to 
help reduce unnecessary healthcare resource use and costs at EOL.  
 However, our study results need to be considered in light of certain limitations. First, this 
study only included MM patients who were 66 years old or older at the time of death. Thus, our 
results may not be generalizable to younger people. Nevertheless, since the median age at 
diagnosis of MM is 69, and around 2/3rd of all MM patients are diagnosed at the age of 65 or 
older, our study sample is likely to be representative of the population of MM patients. Second, 
the analysis was limited to MM patients enrolled in fee-for-service Medicare. Hence, our results 
are not generalizable to elderly MM patients enrolled in Medicare managed care organizations. 
Future studies should examine whether MM patients enrolled in Medicare managed care plans 
had similar results. Third, coding errors in claims data might bias our study results. Fourth, we 
lack information on patient functional status, and their symptom burden, namely, pain and 
fatigue, which are very common amongst MM patients as they approach end of life (Snowden et 
al. 2011; Porta-Sales et al. 2015; Niscola et al. 2007). Future studies should consider accounting 
for patients’ performance and symptom burden, if possible, to assess the impact of palliative care 
consultations on receiving aggressive EOL care, and healthcare resource use and costs at EOL.  
Conclusion 
Our study used a population-based cohort of elderly MM patients to assess trends in 
aggressiveness of EOL care outcomes over time. While certain indicators of aggressive EOL 
care remained stable over time, we observed an increasing trend for multiple ED visits and ICU 
stays. Moreover, this study assessed the impact of palliative care consultations on receiving 
aggressive EOL care, and healthcare resource use and costs at EOL. Results indicate that early 
palliative care consultations have the potential to reduce aggressive EOL care, and curtail 
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healthcare resource use and costs at EOL. Findings from this study can aid policy discussions 
and help plan interventions aimed to decreasing aggressive EOL care, and aid development and 
integration of early palliative care consultations in routine MM care.  
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Table 3.1 Characteristics of elderly MM patients who died during 2007-2016 
Demographic and Clinical 
Characteristics 
Category N = 5,151 
Living in urban areas (n, %) No 564 10.9% 
Yes 4,587 89.1% 
Geographical region (n, %) Northeast 1,041 20.2% 
South 1,410 27.4% 
Midwest 647 12.6% 
West 2,053 39.8% 
Gender (n, %) Male 2,515 48.8% 
Female 2,636 51.2% 
Race (n, %) White 3,798 73.7% 
African American 848 16.5% 
Hispanic 178 3.5% 
Other 327 6.3% 
Charlson Comorbidity Index 
score category (n, %) 
0 339 6.6% 
1 476 9.2% 
2 607 11.8% 
3+ 3,729 72.4% 
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Age category (n, %) 66-69 618 12.0% 
70-74 1,091 21.2% 
75-79 1,103 21.4% 
80-84 1,054 20.5% 
85+ 1,285 24.9% 
Disability status (n, %) No 1,511 29.3% 
Yes 3,640 70.7% 
Marital Status (n, %) Single 505 9.8% 
Married 2,443 47.4% 
Separated/Divorced 477 9.3% 
Widowed 1,402 27.2% 
Other 324 6.3% 
Year of Death (n, %) 2007 136 2.6% 
2008 246 4.8% 
2009 342 6.6% 
2010 418 8.1% 
2011 479 9.3% 
2012 600 11.7% 
2013 622 12.1% 
2014 784 15.2% 
2015 809 15.7% 
2016 715 13.9% 
Palliative Care Consultation No 3,542 68.8% 
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Yes 1,609 31.2% 
Survival Months (median, 
Q1-Q3) 
  21 6,43 
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Table 3.2.1 Trend in multiple ED visits during EOL among elderly MM patients who died, 
2007-2016 
Year of 
Death 
> 1 ED visit (n, %) 
No Yes 
2007 
103 
(75.7%) 
33 
(24.3%) 
2008 
200 
(81.3%) 
46 
(18.7%) 
2009 
269 
(78.7%) 
73 
(21.3%) 
2010 
336 
(80.4%) 
82 
(19.6%) 
2011 
372 
(77.7%) 
107 
(22.3%) 
2012 
457 
(76.2%) 
143 
(23.8%) 
2013 
493 
(79.3%) 
129 
(20.7%) 
2014 
602 
(76.8%) 
182 
(23.2%) 
2015 
618 
(76.4%) 
191 
(23.6%) 
2016 
529 
(74.0%) 
186 
(26.0%) 
Cochrane Armitage trend test: p = 
0.017 
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Table 3.2.2 Trend in greater than 14 days of inpatient stay during EOL among elderly MM 
patients who died, 2007-2016 
Year of 
Death 
> 14 days inpatient LOS (n, 
%) 
No Yes 
2007 94 (69.1%) 42 (30.9%) 
2008 186 (75.6%) 60 (24.4%) 
2009 260 (76.0%) 82 (24.0%) 
2010 319 (76.3%) 99 (23.7%) 
2011 359 (75.0%) 120 (25.0%) 
2012 464 (77.3%) 136 (22.7%) 
2013 503 (80.9%) 119 (19.1%) 
2014 601 (76.7%) 183 (23.3%) 
2015 640 (79.1%) 169 (20.9%) 
2016 569 (79.6%) 146 (20.4%) 
Cochrane-Armitage trend test: p =0.004 
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Table 3.2.3 Trend in multiple inpatient admissions during EOL among elderly MM 
patients who died, 2007-2016 
Year of 
Death 
> 1 inpatient admission (n, 
%) 
No Yes 
2007 97 (71.3%) 39 (28.7%) 
2008 189(76.8%) 57 (23.2%) 
2009 261 (76.3%) 81 (23.7%) 
2010 319 (76.3%) 99 (23.7%) 
2011 358 (74.7%) 121 (25.3%) 
2012 453 (75.5%) 147 (24.5%) 
2013 491 (78.9%) 131 (21.1%) 
2014 589 (75.1%) 195 (24.9%) 
2015 627 (77.5%) 182 (22.5%) 
2016 562 (78.6%) 153 (21.4%) 
Cochrane-Armitage trend test: p = 0.113 
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Table 3.2.4 Trend in ICU stay during EOL among elderly MM patients who died, 2007-
2016 
Year of 
Death 
ICU stay (n, %) 
No Yes 
2007 98 (72.1%) 38 (27.9%) 
2008 178 (72.4%) 68 (27.6%) 
2009 243 (71.1%) 99 (28.9%) 
2010 280 (67.0%) 138 (33.0%) 
2011 338 (70.6%) 141 (29.4%) 
2012 417 (69.5%) 183 (30.5%) 
2013 437 (70.3%) 185 (29.7%) 
2014 542 (69.1%) 242 (30.9%) 
2015 526 (65.0%) 283 (35.0%) 
2016 467 (65.3%) 248 (34.7%) 
Cochrane-Armitage trend test: p = 0.005 
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Table 3.2.5 Trend in death in hospital among elderly MM patients who died, 2007-2016 
Year of 
Death 
Death in hospital (n, %) 
No Yes 
2007 78 (57.3%) 58 (42.7%) 
2008 166 (67.5%) 80 (32.5%) 
2009 228 (66.7%) 114 (33.3%) 
2010 274 (65.6%) 144 (34.4%) 
2011 318 (66.4%) 161 (33.6%) 
2012 396 (66.0%) 204 (34.0%) 
2013 438 (70.4%) 184 (29.6%) 
2014 534 (68.1%) 250 (31.9%) 
2015 587 (72.6%) 222 (27.4%) 
2016 503 (70.4%) 212 (29.6%) 
Cochrane-Armitage trend test: p < 0.001 
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Table 3.2.6 Trend in chemotherapy use in the last 14 days of life among elderly MM 
patients who died, 2007-2016 
Year of 
Death 
Chemo use in last 14 days of 
life (n, %) 
No Yes 
2007 135 (99.3%) 1 (0.7%) 
2008 246 (100%) 0 (0%) 
2009 340 (99.4%) 2 (0.6%) 
2010 418 (100%) 0 (0%) 
2011 475 (99.2%) 4 (0.8%) 
2012 592 (98.7%) 8 (1.3%) 
2013 613 (98.6%) 9 (1.4%) 
2014 777 (99.1%) 7 (0.9%) 
2015 798 (98.6%) 11 (1.4%) 
2016 709 (99.2%) 6 (0.8%) 
Cochrane-Armitage trend test: p=0.060 
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Table 3.2.7 Trend in any aggressive EOL care among elderly MM patients who died, 2007-
2016 
Year of 
Death 
Any aggressive EOL care (n, 
%) 
No Yes 
2007 54 (39.7%) 82 (60.3%) 
2008 114 (46.3%) 132 (53.7%) 
2009 144 (42.1%) 198 (57.9%) 
2010 191 (45.7%) 227 (54.3%) 
2011 217 (45.3%) 262 (54.7%) 
2012 267 (44.5%) 333 (55.5%) 
2013 291 (46.8%) 331 (53.2%) 
2014 349 (44.5%) 435 (55.5%) 
2015 366 (45.2%) 443 (54.8%) 
2016 315 (44.1%) 400 (55.9%) 
Cochrane-Armitage trend test: p=0.703 
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Table 3.2.8 Joinpoint regression analysis for trends in aggressive EOL care outcomes 
among elderly MM patients who died, 2007-2016 
Outcome Model 
Selected 
p (linear 
trend) 
> 1 ED visits  Joinpoints: 0 0.029 
Inpatient LOS > 14 days Joinpoints: 0 0.014 
> 1 Inpatient admissions Joinpoints: 0 0.104 
ICU stay Joinpoints: 0 0.011 
Death in hospital Joinpoints: 0 0.006 
Any aggressive EOL 
care Joinpoints: 0 0.515 
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Table 3.3.1 Clinical and sociodemographic characteristics of elderly MM patients who died during 2007-2016,  
with and without PCC visits 
Demographic and Clinical 
Characteristics 
Category No PCC group 
 (n = 1,588) 
PCC group 
 (n = 1,588) 
Standardized 
Mean 
Difference 
p 
Living in urban areas (n, 
%) 
No 135 8.5% 146 9.2% 
-0.024 0.278 
Yes 1,453 91.5% 1,442 90.8% 
Geographical region (n, 
%) 
Northeast 362 22.8% 343 21.6% 
0.044 0.173 
South 337 21.2% 347 21.8% 
Midwest 185 11.7% 203 12.8% 
West 704 44.3% 695 43.8% 
Gender (n, %) Male 770 48.5% 754 47.5% 
0.02 0.294 
Female 818 51.5% 834 52.5% 
Race (n, %) White 1,187 74.7% 1,170 73.7% 
0.028 0.683 
African American 251 15.8% 263 16.6% 
Hispanic 38 2.4% 42 2.6% 
Other 112 7.1% 113 7.1% 
Charlson Comorbidity 
Index score category (n, 
%) 
0 98 6.2% 109 6.9% 
0.039 0.476 
1 125 7.9% 132 8.3% 
2 182 11.5% 189 11.9% 
3+ 1,183 74.4% 1,158 72.9% 
Age category (n, %) 66-69 210 13.2% 216 13.6% 
0.041 0.228 
70-74 365 23.0% 355 22.4% 
75-79 342 21.5% 366 23.0% 
80-84 319 20.1% 307 19.3% 
85+ 352 22.2% 344 21.7% 
Disability status (n, %) No 440 27.7% 444 28.0% 
-0.001 0.771 
Yes 1,148 72.3% 1,144 72.0% 
Marital Status (n, %) Single 147 9.3% 156 9.8% 0.052 0.203 
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Married 797 50.2% 772 48.6% 
Separated/Divorced 138 8.7% 155 9.8% 
Widowed 407 25.6% 397 25.0% 
Other 99 6.2% 108 6.8% 
Survival Months (median, 
Q1-Q3)   18 5,39 27 9,50 - 
<0.001 
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Table 3.3.2 Clinical and sociodemographic characteristics of elderly MM patients who died during 2007-2016,  
with late PCC visit and without PCC visits 
Demographic and Clinical 
Characteristics 
Category No PCC group 
 (n = 1,074) 
PCC group 
 (n = 1,074) 
Standardized 
Mean 
Difference 
p 
Living in urban areas (n, 
%) 
No 102 9.5% 107 10.0% 
-0.016 0.553 
Yes 972 90.5% 967 90.0% 
Geographical region (n, 
%) 
Northeast 258 24.0% 234 21.8% 
0.063 0.098 
South 234 21.8% 244 22.7% 
Midwest 126 11.7% 140 13.0% 
West 456 42.5% 456 42.5% 
Gender (n, %) Male 551 51.3% 544 50.7% 
0.013 0.581 
Female 523 48.7% 530 49.3% 
Race (n, %) White 818 76.2% 806 75.1% 
0.035 0.698 
African American 150 14.0% 163 15.2% 
Hispanic 27 2.5% 26 2.4% 
Other 79 7.3% 79 7.3% 
Charlson Comorbidity 
Index score category (n, 
%) 
0 65 6.1% 77 7.2% 
0.063 0.192 
1 96 8.9% 100 9.3% 
2 128 11.9% 140 13.0% 
3+ 785 73.1% 757 70.5% 
Age category (n, %) 66-69 134 12.5% 145 13.5% 
0.053 0.23 
70-74 255 23.7% 244 22.7% 
75-79 246 22.9% 262 24.4% 
80-84 222 20.7% 214 19.9% 
85+ 217 20.2% 209 19.5% 
Disability status (n, %) No 359 33.4% 383 35.7% 
-0.047 0.046 
Yes 715 66.6% 691 64.3% 
Marital Status (n, %) Single 84 7.8% 93 8.7% 0.057 0.344 
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Married 576 53.6% 553 51.5% 
Separated/Divorced 88 8.2% 97 9.0% 
Widowed 259 24.1% 257 23.9% 
Other 67 6.3% 74 6.9% 
Survival Months (median, 
Q1-Q3)   18 5,38 27 8,50 - 
<0.001 
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Table 3.3.3 Clinical and sociodemographic characteristics of elderly MM patients who died during 2007-2016,  
with early PCC visit and without PCC visits 
Demographic and Clinical 
Characteristics 
Category No PCC group 
 (n = 514) 
PCC group 
 (n = 514) 
Standardized 
Mean 
Difference 
p 
Living in urban areas (n, 
%) 
No 33 6.4% 39 7.6% 
-0.046 0.289 
Yes 481 93.6% 475 92.4% 
Geographical region (n, 
%) 
Northeast 104 20.2% 109 21.2% 
0.04 0.578 
South 103 20.0% 103 20.0% 
Midwest 59 11.5% 63 12.3% 
West 248 48.3% 239 46.5% 
Gender (n, %) Male 219 42.6% 210 40.9% 
0.036 0.286 
Female 295 57.4% 304 59.1% 
Race (n, %) White 369 71.8% 364 70.8% 
0.062 0.511 
African American 101 19.7% 100 19.5% 
Hispanic 11 2.1% 16 3.1% 
Other 33 6.4% 34 6.6% 
Charlson Comorbidity 
Index score category (n, 
%) 
0 33 6.4% 32 6.2% 
0.04 0.874 
1 29 5.6% 32 6.2% 
2 54 10.5% 49 9.5% 
3+ 398 77.5% 401 78.1% 
Age category (n, %) 66-69 76 14.8% 71 13.8% 
0.048 0.803 
70-74 110 21.4% 111 21.6% 
75-79 96 18.7% 104 20.2% 
80-84 97 18.9% 93 18.1% 
85+ 135 26.2% 135 26.3% 
Disability status (n, %) No 81 15.8% 61 11.9% 
0.113 0.003 
Yes 433 84.2% 453 88.1% 
Marital Status (n, %) Single 63 12.3% 63 12.3% 0.059 0.592 
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Married 221 43.0% 219 42.6% 
Separated/Divorced 50 9.7% 58 11.3% 
Widowed 148 28.8% 140 27.2% 
Other 32 6.2% 34 6.6% 
Survival Months (median, 
Q1-Q3)   18 6,41 26 10,50 - 
0.001 
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Table 3.4.1 Unadjusted comparisons between any PCC and no PCC groups on aggressive EOL care,  
healthcare resource utilization and costs 
Outcomes Category 
No PCC group  
(n=1,588) 
PCC group  
(n=1,588) 
p 
> 1 ED visits (n, %) No 1,262 79.5% 1,163 73.2% 
<0.001 
Yes 326 20.5% 425 26.8% 
Inpatient LOS > 14 days (n, %) No 1,254 79.0% 1,187 74.8% 
0.005 
Yes 334 21.0% 401 25.2% 
> 1 Inpatient admissions (n, %) No 1,263 79.5% 1,155 72.7% 
<0.001 
Yes 325 20.5% 433 27.3% 
ICU stay (n, %) No 1,139 71.7% 974 61.3% 
<0.001 
Yes 449 28.3% 614 38.7% 
Death in hospital (n, %) No 1,139 71.7% 1,008 63.5% 
<0.001 
Yes 449 28.3% 580 36.5% 
Chemotherapy use in last 14 
days (n, %) 
No 1,572 99.0% 1,571 98.9% 
0.858 
Yes 16 1.0% 17 1.1% 
Any aggressive EOL care (n, 
%) 
No 784 49.4% 562 35.4% 
<0.001 
Yes 804 50.6% 1,026 64.6% 
HCRU in EOL (mean, sd)   1.17 1.32 1.49 1.3 <0.001 
EOL costs (mean, sd)   $19,997.6  20,375.5 $25,055.8  20,365.4 <0.001 
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Table 3.4.2 Unadjusted comparisons between late PCC and no PCC groups on aggressive EOL care,  
healthcare resource utilization and costs 
Outcomes Category 
No PCC group  
(n=1,074) 
PCC group  
(n=1,074) 
p 
> 1 ED visits (n, %) No 850 79.1% 723 67.3% 
<0.001 
Yes 224 20.9% 351 32.7% 
Inpatient LOS > 14 days (n, %) No 837 77.9% 734 68.3% 
<0.001 
Yes 237 22.1% 340 31.6% 
> 1 Inpatient admissions (n, %) No 845 78.7% 700 65.2% 
<0.001 
Yes 229 21.3% 374 34.8% 
ICU stay (n, %) No 763 71.0% 542 50.5% 
<0.001 
Yes 311 29.0% 532 49.5% 
Death in hospital (n, %) No 760 70.8% 583 54.3% 
<0.001 
Yes 314 29.2% 491 45.7% 
Chemotherapy use in last 14 
days (n, %) 
No 1,061 98.8% 1,058 98.5% 
0.564 
Yes 13 1.2% 16 1.5% 
Any aggressive EOL care (n, 
%) 
No 521 48.5% 212 19.7% 
<0.001 
Yes 553 51.5% 862 80.3% 
HCRU in EOL (mean, sd)   1.18 1.32 1.84 1.21 <0.001 
EOL costs (mean, sd)   $20,785.7  21151.9 $30,646.3 19411.4 <0.001 
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Table 3.4.3 Unadjusted comparisons between early PCC and no PCC groups on aggressive EOL care,  
healthcare resource utilization and costs 
Outcomes Category 
No PCC group  
(n=514) 
PCC group  
(n=514) 
p 
> 1 ED visits (n, %) No 412 80.2% 440 85.6% 
0.022 
Yes 102 19.8% 74 14.4% 
Inpatient LOS > 14 days (n, %) No 417 81.1% 453 88.1% 
0.002 
Yes 97 18.9% 61 11.9% 
> 1 Inpatient admissions (n, %) No 418 81.3% 455 88.5% 
0.001 
Yes 96 18.7% 59 11.5% 
ICU stay (n, %) No 376 73.2% 432 84.1% 
<0.001 
Yes 138 26.5% 82 15.9% 
Death in hospital (n, %) No 379 73.7% 425 82.7% 
<0.001 
Yes 135 26.3% 89 17.3% 
Chemotherapy use in last 14 
days (n, %) 
No 511 99.4% 513 99.8% 
0.317 
Yes 3 0.6% 1 0.2% 
Any aggressive EOL care (n, 
%) 
No 263 51.2% 350 68.1% 
<0.001 
Yes 251 48.8% 164 31.9% 
HCRU in EOL (mean, sd)   1.13 1.31 0.77 1.17 <0.001 
EOL costs (mean, sd)   $18,350.9  18561.0 $13,374.7  17110.8 <0.001 
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Table 3.5 Multivariable analysis for aggressive EOL care between the PCC and no PCC groups 
 
Outcomes No PCC group PCC group 
Odds Ratio 
95% Confidence Interval 
Odds Ratio 
95% Confidence 
Interval 
  no PCC  (n=1,588) Any PCC (n=1,588) 
> 1 ED visits  Reference Reference Reference 1.41 1.18 1.67 
Inpatient LOS > 14 days Reference Reference Reference 1.30 1.10 1.54 
> 1 Inpatient admissions Reference Reference Reference 1.49 1.25 1.75 
ICU stay Reference Reference Reference 1.69 1.45 2.00 
Death in hospital Reference Reference Reference 1.54 1.30 1.79 
Any aggressive EOL care Reference Reference Reference 1.86 1.59 2.16 
  no PCC  (n=1,074) PCC in EOL (n=1,074) 
> 1 ED visits  Reference Reference Reference 1.89 1.52 2.33 
Inpatient LOS > 14 days Reference Reference Reference 1.72 1.41 2.13 
> 1 Inpatient admissions Reference Reference Reference 2.04 1.67 2.50 
ICU stay Reference Reference Reference 2.78 2.22 3.33 
Death in hospital Reference Reference Reference 2.22 1.82 2.70 
Any aggressive EOL care Reference Reference Reference 4.17 3.33 5.26 
  no PCC  (n=514) PCC prior to EOL (n=514) 
> 1 ED visits  Reference Reference Reference 0.70 0.50 0.98 
Inpatient LOS > 14 days Reference Reference Reference 0.59 0.42 0.84 
> 1 Inpatient admissions Reference Reference Reference 0.57 0.40 0.82 
ICU stay Reference Reference Reference 0.52 0.38 0.71 
Death in hospital Reference Reference Reference 0.58 0.42 0.79 
Any aggressive EOL care Reference Reference Reference 0.47 0.35 0.61 
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Table 3.6 Multivariable analysis for healthcare resource utilization (HCRU) and costs at EOL  
between the PCC and no PCC groups 
Outcomes No PCC group  PCC group  Incremental Difference 
Mean Mean Mean 
95% Confidence 
Interval 
  
No PCC  
(n = 1,588) 
Any PCC  
(n=1,588)   
HCRU in EOL  1.17 1.50 0.33 0.33 0.34 
EOL cost ( in US $) 19,883.7 25,199.4 5,315.7 5,308.8 5,323.1 
  
No PCC  
(n = 1,074) 
PCC in EOL  
(n = 1,074)   
HCRU in EOL  1.18 1.84 0.66 0.65 0.67 
EOL cost ( in US $) 20,618.0 30,890.4 10,272.4 10,229.6 10,311.4 
  
No PCC  
(n = 514) 
PCC prior to 
EOL  
(n = 514)   
HCRU in EOL  1.12 0.77 0.35 0.34 0.35 
EOL cost ( in US $) 18,281.6 13,435.4 4,846.2 4,818.4 4,872.3 
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Figure 3.1 Joinpoint regression for trend in multiple ED visits during EOL among elderly 
MM patients who died, 2007-2016  
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Figure 3.2 Joinpoint regression for trend in greater than 14 days of inpatient stay during 
EOL among elderly MM patients who died, 2007-2016 
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Figure 3.3 Joinpoint regression for trend in multiple inpatient admissions during EOL 
among elderly MM patients who died, 2007-2016 
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Figure 3.4 Joinpoint regression for trend in ICU stay during EOL among elderly MM 
patients who died, 2007-2016 
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Figure 3.5 Joinpoint regression for trend in death in hospital among elderly MM patients 
who died, 2007-2016 
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Figure 3.6 Joinpoint regression for trend in any aggressive EOL care during EOL among 
elderly MM patients who died, 2007-2016 
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CHAPTER 5 
Dissertation Summary and Future Research 
Summary 
This study used a population-based cohort of elderly NDMM patients to depict treatment 
patterns and assess the comparative safety and effectiveness among those who received first line 
LEN-based treatment versus those who received first line BORT-based treatment. Our study 
results corroborated that with several novel MM agents coming onto the market in the past 10 
years, MM treatment has seen a dynamic shift, with novel agents firmly established as the 
standard of care. We have found that the majority of the elderly NDMM patients received first 
line novel agent-based therapy, and the uptake of combination MM agents in subsequent lines of 
therapy has been rising. Additionally, our study demonstrates an overall survival benefit and 
similar toxicity risk for patients receiving first line LEN-based continuous or maintenance 
treatment over those who received first line BORT-based treatment. 
 Using a data-driven approach (Joinpoint regression), it determined the duration of the 
initial phase to be 4 months post MM diagnosis among Medicare beneficiaries. For the terminal 
phase, it found a significant change in the monthly cost trends at the 3-month and 8-month 
periods prior to death. The results highlighted the substantial economic burden associated with 
MM care, in spite of the disease having low prevalence as compared to some of the other 
cancers. The incremental phase-specific costs were highest for the initial care phase, followed by 
the terminal phase, with costs being slightly lower for the continuing care phase, and lowest for
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 the pre-diagnosis phase. Inpatient and outpatient costs were the major drivers of costs in all the 
four phases. Pharmacy costs were a significant driver of costs in the initial and terminal phases, 
and were the biggest cost driver in the continuing care phase. 
Moreover, it assessed trends in aggressiveness of EOL care outcomes over time. While 
certain indicators of aggressive EOL care remained stable over time, we observed an increasing 
trend for multiple ED visits and ICU stays. Moreover, this study assessed the impact of palliative 
care consultations on receiving aggressive EOL care, and healthcare resource use and costs at 
EOL. Results indicate that early palliative care consultations have the potential to reduce 
aggressive EOL care, and curtail healthcare resource use and costs at EOL. 
Future Directions 
First, our study sample consisted of elderly NDMM patients enrolled in fee-for-service 
Medicare. Hence, the results from our may not be generalizable to NDMM patients who are 
younger or elderly patients enrolled in Medicare Advantage plans. Future studies should 
investigate this relationship among younger or elderly patients enrolled in Medicare Advantage 
plan to assess its generalizability in other populations. Second, when clinical decisions are made 
for treatment choice, several clinical factors including cancer stage, disease prognosis, and 
functional status will be taking into consideration However, these factors are not available in the 
SEER-linked Medicare data used in this study. Future studies should take cancer staging and 
disease prognosis into account while comparing safety and survival between various treatments. 
Third, our analyses on incremental lifetime and phase-specific costs of MM could not be 
stratified by cancer stage. Future studies should estimate MM lifetime and phase-specific costs 
stratified by cancer stage to see if the cost patterns vary by cancer stage. Fourth, we lack 
information on patient functional status, and their symptom burden, namely, pain and fatigue, 
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which are very common amongst MM patients as they approach end of life. Future studies 
should consider accounting for patients’ performance and symptom burden, if possible, to assess 
the impact of palliative care consultations on receiving aggressive EOL care, and healthcare 
resource use and costs at EOL. 
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